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Abstract
The ubiquitin-proteasome system (UPS) not only maintains cellular proteostasis, but plays an essential
role in multiple vital cellular processes, including survival and growth. Proteasomal inhibitors, such as
bortezomib, have been shown to have effective anti-cancer properties, verifying the UPS as a viable
drug target in cancer treatment. Yet, these compounds have encountered problems regarding toxicity,
and inevitably development of resistance. The search for alternative targets within the UPS has revealed
the 19S regulatory particle-associated deubiquitinases USP14 and UCHL5. Their inhibition blocks the
deubiquitinating activity necessary for protein degradation by the proteasome. This has been shown to
have cytotoxic effects in a range of cancer cells lines, as well as inhibiting tumor growth in several in
vivo models. The small molecule inhibitor b-AP15 and its optimized lead VLX1570 were first discovered
and characterized by the Linder research group at Karolinska Institute. Though thought to be highly
promiscuous due to its α,β- unsaturated ketone motif, b-AP15 was demonstrated to selectively bind
and inhibit the proteasomal deubiquitinases USP14 and UCHL5, with preferential binding to USP14.
Inhibition of USP14 by b-AP15 results in a strong proteotoxic stress characterized by elevated levels of
poly-ubiquitin, activation of the ER stress response, and oxidative stress, followed by apoptosis. We show
here that the mechanism of b-AP15-induced apoptosis is characteristic of proteasome inhibition, but
significantly differs from the effects of catalytic proteasome inhibitors. The results of b-AP15 treatment
manifest as: severe proteotoxicity, mitochondrial damage without mitophagy induction, and lack of
cytoprotective aggresome formation. Available evidence supports that the cellular response to b-AP15
is primarily dependent on USP14.
Additionally, we use a drug screen of compounds that share a reactive unsaturated ketone motif
with b-AP15, to show their potential pharmacological applications, relative selectivity for USP14, and
ability to inhibit the UPS.
This thesis describes in detail the proteotoxic effects induced by b-AP15 and its derivative VLX1570,
and shows that despite its potential reactivity, b-AP15 selectively targets USP14. Similarly reactive
compounds are shown to also display selectivity for the 19S deubiquitinases, indicating a potential for
phamacological application in cancer therapy.

List of Publications
I. Xin Wang, Magdalena Mazurkiewicz, Ellin-Kristina Hillert, Maria Hägg Olofsson, Ste-
fan Pierrou, Per Hillertz, Joachim Gullbo, Karthik Selvaraju, Aneel Paulus, Sharoon Akhtar,
Felicitas Bossler, Asher Chanan Khan, Stig Linder, and Padraig D’Arcy
The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-
specific protease-14 and induces apoptosis of multiple myeloma cells
Scientific Reports 2016; 6:269–279.
II. Xiaonan Zhang, Paola Pellegrini, Amir Ata Saei,Ellin-Kristina Hillert, Magdalena Mazurkiewicz,
Maria Hägg Olofsson, Roman A Zubarev, Padraig B D’Arcy and Stig Linder
The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochon-
drial damage
Biochemical Phamacology 2018; 156:291–301.
III. Ellin-Kristina Hillert, Slavica Brnjic, Xiaonan Zhang, Magdalena Mazurkiewicz, Karthik Sel-
varaju, Arjan Mofers, Amir Ata Saei, Roman Zubarev, Stig Linder and Padraig D’Arcy
Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytopro-
tective aggresome formation
Cancer Letters 2019; 448:70–83
IV. Karthik Selvaraju, Arjan Mofers, Paola Pellegrini, Johannes Salomonsson, Alexandra Ahlner,
Vivian Morad,Ellin-Kristina Hillert, Belen Espinosa, Elias S.J. Arnér, Lasse Jensen, Jonas Malm-
ström, Maria V. Turkina, Padraig D’Arcy, Michael A. Walters, Maria Sunnerhagen, and
Stig Linder
Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin pro-
teasome system
Manuscript submitted for publication.Scientific Reports, under revision
V. Ellin-Kristina Hillert, Karthik Selvaraju, Arjan Mofers, Johannes Gubat, Stig Linder and
Padraig D’Arcy, Studies on the specificity of the deubiquitinase inhibitor b-AP15
Manuscript
The articles will be referred to in the text by their Roman numerals, and are reproduced in
full at the end of the thesis.
Related publications
• Magdalena Mazurkiewicz,Ellin-Kristina Hillert, Xin Wang, Paola Pellegrini, Maria Hägg Olof-
sson, Karthik Selvaraju, Padraig D’Arcy, and Stig Linder
Acute lymphoblastic leukemia cells are sensitive to disturbances in protein home-
ostasis induced by proteasome deubiquitinase inhibition
Oncotarget 2017; 8(13):21115–21127.
• Xin Wang, Magdalena Mazurkiewicz, Ellin-Kristina Hillert, Maria Hägg Olofsson, Ste-
fan Pierrou, Per Hillertz, Joachim Gullbo, Karthik Selvaraju, Aneel Paulus, Sharoon Akhtar,
Felicitas Bossler, Asher Chanan Khan, Stig Linder, and Padraig D’Arcy
Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity
for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
Scientific Reports 2016; 6:30667.
Contents
1 Introduction 1
2 Background 2
2.1 The Ubiquitin-Proteasome System . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
2.2 Ubiquitination and Regulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2.3 The Proteasome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.3.1 Structure and Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.4 Proteasomal degradation of substrates . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.5 Proteasomal Deubiquitinases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.5.1 Rpn11/POH1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.5.2 UCHL5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.5.3 USP14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.6 Proteotoxic stress and Proteostasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.6.1 ER stress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.6.2 Aggregate formation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.6.3 Autophagy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.6.4 Cell Death . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.7 The UPS in Cancer and Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.7.1 The UPS in Neurodegeneration . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.7.2 The UPS in Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.8 Targeting the UPS in Cancer Treatment . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.8.1 Targeting the ubiquitin cascade . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.8.2 Targeting 20S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.8.3 Targeting 19S . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.9 Targeting 19S Deubiquitinases in Cancer Treatment . . . . . . . . . . . . . . . . 24
2.10 Deubiquitinase Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.10.1 Curcumin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.10.2 AC17 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.10.3 WP1130 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.10.4 Auranofin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.10.5 Metal pyrithiones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.10.6 G5/2c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.10.7 IU1 and the USP14 controversy . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.11 b-AP15 as a DUB inhibitor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.11.1 b-AP15 structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.11.2 b-AP15-induced proteotoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.11.3 b-AP15 derivatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3 Aims of this Thesis 32
4 Results 33
4.1 Paper I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
4.2 Paper II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
4.3 Paper III . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
4.4 Paper IV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
4.5 Paper V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
5 Discussion 41
5.1 Cellular effects of b-AP15 and VLX1570 . . . . . . . . . . . . . . . . . . . . . . . . 41
5.2 Biochemical basis of b-AP14 effects and role of USP14 . . . . . . . . . . . . . . . 44
5.3 Ethical Considerations and Limitations . . . . . . . . . . . . . . . . . . . . . . . . . 49
6 Conclusions 50
7 Future Perspectives 51
References 52
Acknowledgements 84
List of Abbreviations
ATF6 Activating Transcription Factor 6
ATP Adenosine Triphosphate
BRCA1 Breast Cancer Type 1 Susceptibility Protein
CdPT Cadmium pyrithione
CHIP C-terminal of Hsp70 Interacting Protein (E3 Ligase)
CP Core Particle of the Proteasome
CuPT Copper pyrithione
DUB Deubiquitinase
E1 Ubiquitin-activating enzyme
E2 Ubiquitin-conjugating enzyme
E3 Ubiquitin Ligase
E6 HPV oncoprotein E6
E6-AP Oncoprotein E6 associated protein
eIF2α Eukaryotic initiation factor 2 α
ER Endoplasmic reticulum
ERAD ER-associated degradation
GTP Guanosine Triphosphate
HECT Homology to E6-AP C terminal - E3 ligase family
HPV Human Papilloma Virus
Hsp Heat-shock protein
IAP Inhibitor of Apoptosis protein
IRE1 Inositol-requiring enzyme 1
JAB1 c-Jun activation domain-binding protein-1
JAMM JAB1-MPN-MOV34 motif
JNK c-Jun N-terminal kinase
Keap1 Kelch-like ECH-associated protein 1
MDM2 Mouse double minute 2 homolog - E3 ligase
NFκB Nuclear Factor kappa B
Nrf2 NF-E2-related factor 2 - transcription factor
OCR oxygen consumption rate
P-SII Partially selective Isopeptidase Inhibitor
p53 Tumor suppressor protein 53
PAINS Pan assay interference compounds
PERK Protein Kinase RNA-like endoplasmic reticulum kinase
PDB Protein DataBank
PI3K-III class III phosphatidylinositol 3-kinase complex
PINK1 PTEN-induced putative kinase 1
POH1 Rpn11 deubiquitinase
PGPH Peptidyl-glutamyl hydrolysing
RIPA Radioimmunoprecipitation assay buffer
RBR RING between RING - E3 ligase family
RING Really interesting new gene - E3 Ligase family
ROS Reactive Oxygen Species
RP Regulatory Particle of the Proteasome
Rpn Regulatory particle non-ATPase
Rpt Regulatory Particle Triple A ATPase
SAHA Suberoylanilide hydroxamic acid/Vorinostat
SDS Sodium Docecylsulfate
SQSTM1 sequestrome 1 / p62
TDP-43 TAR DNA-binding protein-43
TNF Tumor necrosis factor
TRAIL TNF-related apoptosis-inducing ligand
TrxR thioredoxin reductase
TUBE tandem ubiquitin-binding entities assay
Ub Ubiquitin
UBA Ubiquitin-associated domain
UBL Ubiquitin-like domain
UCHL5 Ubiquitin carboxy-terminal hydrolase L5
UPR Unfolded protein response
USP14 Ubiquitin-specific protease 14
UPS Ubiquitin-Proteasome System
VCP Valosin-containing protein - p97 AAA-ATPase
VHL Von Hippel–Lindau tumor suppressor
YDR Tyr-Asp-Arg motif
ZnPT Zinc pyrithione
Chapter 1
Introduction
“Medicine is not only a science; it is also an art ... it deals with the very processes of
life, which must be understood before they may be guided.”
—Paracelsus
As Paracelsus reminds us, understanding the mechanism behind the action of a drug is an
essential component of medical practice and research.
Especially in cancer research, a frequent practice it to report that a certain compound
induces cell death, without further investigating why exactly it is doing so. Unsurprisingly,
"death" is really not a very informative result, and it is certainly not enough to claim that a
compound would make an effective cancer treatment. In order to understand how we can use
a novel compound, we must always strive to understand how and why it works.
The focus of this thesis is understanding the mechanism and effects of b-AP15 - a novel
inhibitor of the ubiquitin proteasome system - which targets the deubiquitinase USP14. By
extension, this thesis also discusses the role of USP14 in proteasomal degradation, which has
been a point of some controversy in the field of drug research over the past decade. This thesis
therefore has two main focal points:
Firstly, this thesis deals with the cellular effects of b-AP15 on cancer cell survival (Paper I),
mitochondrial function & damage (Paper II), and intracellular transport & aggresome formation
(Paper III).
Secondly, this thesis focuses on the chemical and biological basis for the effects of b-AP15,
and several of its derivatives. It describes in detail the rationale behind a drug-screen of com-
pounds sharing a common enone motif with b-AP15 (Paper IV), and the dependence of b-AP15’s
cellular effects on the proteasomal deubiquitinase USP14 (Paper V).
Chapter 2
Background
2.1 The Ubiquitin-Proteasome System
The UPS is the major pathway of protein degradation in eukaryotic cells. It consists of a 2.5MDa
catalytic complex and its associated ubiquitinating pathway - the ubiquitin system - which flags
protein substrates for degradation. The proteasome itself consists of a catalytic core particle
(CP, 20S) and one or two associated regulatory particles (RP, 19S), which together make up the
26S proteasome complex.[6, 7]
Originally thought to only be a recycling pathway for damaged proteins, it was not until
the 1980s that the importance of this degradation machinery became known, revealing that
protein stability is primarily determined by their degradation. Up until then, the maintenance of
proteostasis was primarily attributed to translation, transcription and innate stability of proteins
[8, 9, 10], and it was thought that degradation was primarily managed by lysosomes [11, 12,
13]. However, it was then observed that lysosome inhibition or absence does not prevent protein
turnover, revealing that the UPS plays a central role in maintaining proteostasis, degrading
as much as 80% of cellular protein [14, 15]. At the same time, the importance of the small
protein ubiquitin in proteasomal degradation was uncovered. It has been shown that ubiquitin
is an essential component of the degradation machinery, and that protein turnover hinges
entirely on ATP-dependent linkage of ubiquitin to target proteins [16, 17, 18]. The discovery of
this ubiquitin-dependent proteasomal degradation significantly advanced the understanding
of cellular proteostasis, and lead to A. Ciechanover, A. Hershko and I. Rose being awarded the
2004 Nobel Prize in Chemistry.
Proteins targeted by the UPS include cell cycle regulators, receptors, signaling molecules,
tumor suppressors and oncogenes[19, 20, 21, 22, 23, 24]. The proteasome is therefore tightly
coupled to essentially all cellular processes, including the cell cycle, growth, signal processing,
endocytosis and cell death [25, 26]. As such, its structure, assembly and function are stringently
regulated by various mechanisms. Its central role makes the UPS a promising target not only
in cancer therapy, but also for the treatment of neurodegenerative disorders, immunological
dysfunction, cystic fibrosis and muscle wasting disorders [27, 28, 29, 30, 31].
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Figure 2.1: The Ubiquitin Conjugation system consisting of E1, E2 and E3 enzymes that work in sequence
to link single ubiquitin moieties to substrate proteins in an ATP-dependent manner.
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2.2 Ubiquitination and Regulation
Upstream of the 26S proteasome lies the Ubiquitin System. Its function is to recognize 26S
protein substrates, and to tag them with the 76-amino-acid protein ubiquitin (Figure 2.1).
Ubiquitin is a highly abundant and conserved protein [32, 33]. The ubiquitin-tag targets
the substrate to the proteasome for degradation, but can serve other functions as well. Ubiq-
uitination requires the action of three different types of enzymes. First, the E1 (Ubiquitin
Activating) Enzyme binds free ubiquitin and activates its C-terminal glycine residue (G76) in
an ATP-dependent manner, creating ubiquitin adenylate. This glycine residue protrudes some-
what from the bulk of the protein, and is the sole known location at which covalent linkages
to ubiquitin occur [34, 33]. The active glycine residue then binds to a cysteine on E1 [35, 36].
Secondly, the activated ubiquitin is transferred to a cysteine residue on the E2 (Ubiquitin Conju-
gating) enzyme. From there ubiquitina is finally transferred to an E3 enzyme (Ubiquitin Ligase)
that will catalyze the linkage of the ubiquitin C-terminal glycine to the "-amino group of a
lysine on the target protein via an amide isopeptide linkage. There are over 600 distinct E3
ligases, which are classed into three subfamilies, depending on their structure and the mech-
anism by which they transfer ubiquitin to their substrate [37]. The most prolific family of E3
ligases are likely the RING (Really interesting new gene) finger ligases, which share the RING
finger motif and simultaneously bind the E2-bound ubiquitin and the substrate to catalyze a
direct ubiquitin transfer [38, 39]. The other two families are the HECT (homology to E6-AP
C-terminus) E3 ligases, and RBR (RING between RING) E3 ligases. Both catalyze a sequential
ubiquitin transfer by first accepting ubiquitin from the E2 enzyme, and transferring it onto a
substrate in a second reaction [40, 41].
Only a single E1 enzyme exists. It can bind to all existing E2s, and transfer the activated
ubiquitin for transient linkage. With multiple E2s, and several large families of E3 enzymes,
specificity of the resulting ubiquitin tag increases with every step of the ubiquitination process
[31]. Each E2 will only interact with a few select E3s, and each E3 has a high specificity for
a particular substrate [42, 43]. This allows the Ubiquitin system to be tighly and specifically
regulated.
Mono-ubiquitination plays an important role in cell signaling and regulating protein func-
tion [44, 45, 46], however, to target proteins for degradation, longer chains of ubiquitin moieties
are required. To create these, the ubiquitination process is repeated, linking the next ubiquitin
to a lysine on the first ubiquitin moiety resulting in poly-ubiquitin chains. There are at least
8 different subtypes of poly-ubiquitin linkages [47]. The most commonly occurring linkages
connect the C-terminal Gly76 residue to the next ubiquitin’s Lys48 or Lys63 residues. While
Lys63-linked chains are important in non-proteolytic signaling - specifically protein kinase acti-
vation and DNA damage - [48, 43], Lys48 poly-ubiquitin targets substrates to the proteasome
for degradation [49, 50, 31, 27]. A chain of at least four linked ubiquitin moieties is necessary
for substrate recognition by the 26S proteasome [51, 52].
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2.3 The Proteasome
The proteasome is an early evolutionary concept, with a conserved structure that can be found
from archaebacteria to eukaryotes. It is localized in both the nucleus and the cytoplasm [53,
54, 55], and its essential functions are stringently regulated on various levels. Figure 2.2 shows
the structural design of the 26S proteasome.
19S 
Regulatory
Particle
20S Catalytic 
Core Particle
20S β-subunits
20S α-subunits
Figure 2.2: The structure of the 26S proteasome. The 19S RP is shown in dark green, the 20S α subunit
rings are shown in purple, and the 20S β subunit rings are shown in light green (PDB:4CR2) [56, 57].
2.3.1 Structure and Function
The 26S proteasome is a large and complex multimeric structure, consisting of two distinct pro-
tein complexes: the 20S core particle (CP) and the 19S regulatory particle (RP) [58]. The 20S
CP and the 19S RP carry out different functions that are essential to proteasomal degradation,
and will be described in the following sections.
The 20S CP
The 20S CP is a large multimer, containing the catalytic activity of the proteasome. In eukaryotes
it consists of 28 subunits. The subunits are arranged into 4 homoheptameric rings, which are
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axially stacked, forming a barrel structure approximately 15nm long, 11nm wide and enclosing
a cavity of 5nm diameter, with the catalytic activity contained inside. Eukaryotes have 14 distinct
20S subunits: α1−7 and β1−7, and the 20S CP contains two copies of each. Each heptameric
ring is made up exclusively of either α or β subunits. Two β rings form the center of the barrel,
and two α rings form the ends, resulting in a α1−7β1−7β1−7α1−7 structure, with the N-termini
of the subunits pointing inwards (Figure 2.2). All 20S subunits have a similar β-sandwich
structure that is typical of N-terminal nucleophile-hydrolases [58, 59, 60]. Characteristically α
subunits feature an extended N-terminal end, while β subunits are cleaved during proteasome
assembly, to reveal an active threonine residue [61, 62]. However, only three of the β subunits
are catalytically active: β1, β2 and β5 are threonine proteases, carrying a single catalytic
threonine (Thr1) which acts as a nucleophile in hydrolysis of peptide bonds. The N-terminal of
Thr1 acts as the essential proton acceptor to achieve activation, while the surrounding residues
Glu17, Lys33 and Asp166 are also required for catalysis [58, 63, 64]. The catalytic system itself
is formed by the N-termini facing into the center of the barrel structure, with three active sites
on each of the two β rings. The active sites have three major peptidase activities: peptidyl-
glutamyl hydrolyzing (PGPH), trypsin-like and chymotrypsin-like, corresponding to β1, β2
and β5 respectively [59, 65]. Each of the three different active sites has a specific cleavage site
affinity. The β1 PGPH (also referred to as caspase-like) activity cleaves primarily after acidic
residues, β2 cleaves after basic residues, and β5 primarily cleaves after hydrophobic residues
[58, 66].
It was once thought that the distance between, and specificity of these active sites would
determine the size of the resulting cleaved peptides, like a "molecular ruler"[67, 68], with
expected peptide sizes of 7 to 9 amino acids. However,it has been observed that the mammalian
26S proteasome produces a range of peptide lengths from 3 amino acids up to 30, with over 60
percent of peptides shorter than 8 amino acids and a mean length of 6 residues. Additionally,
the bacterial proteasome has 14 active sites - all of which have chymotrypsin-like activity -
yet it produces a similar spread of peptide products. The molecular ruler model therefore no
longer holds up. Instead it has been proposed that substrates are simply degraded until they
are small enough to diffuse out of the proteasome [69, 64]. In general it appears that the
proteasome catalytic activity amounts to more than simply an integration of three different
cleavage activities, and it has been shown that the proteasome can cleave its substrates at
virtually any peptide bond, and that cleavage is influenced both by surrounding subunits, as
well as residues other than the target cleavage site [70, 71, 67].
Arguably the main function of the structural organization of the 20S CP is to isolate and
contain the proteolytic activity and prevent unwanted or uncontrolled degradation. Access to
the catalytic chamber is therefore controlled, making substrate entry the rate limiting step in
proteolysis. In eukaryotes the opening leading into the axial channel of the core particle is
topologically closed by the tightly interwoven N-termini of the α subunits. This auto-inhibition
prevents access for both folded and unfolded protein substrates [61]. The N-terminal of the
α3 subunit in particular plays an essential role in stabilizing the closed conformation of the
core particle. It carries the conserved YDR-motif containing an arginine residue (Arg9) that
2. Background 7
has been shown to contact the N-termini of the surrounding α subunits [59, 61, 71]. To allow
substrate access, a rearrangement of the α N-termini is necessary. This can either be achieved
through binding to endogenous regulators or treatment with mild chemicals, such as sodium
dodecylsulfate (SDS). Most commonly, the rearrangement and activation of the 20S CP is
facilitated by binding to one or two 19S RPs [72, 73].
The 19S RP
The 19S RP is a 700kDa complex that associates with the 20S CP. It binds the ends of the barrel
shaped structure formed by the 20S subunits and facilitates substrate entry and catalysis in an
ATP-dependent manner (Figure 2.2). The 19S RP has at least 19 subunits and can be divided
into two sub-structures, one proximal and one distal to the core particle, referred to as "base"
and "lid" respectively. While the base is required for activation of the 20S proteolytic activity,
the lid is necessary for degradation of ubiquitinated substrates. Both the base and lid contain at
least 8 subunits. The base consists of a heterohexameric ring of AAA-ATPases (ATPase associated
with different cellular activities): Rpt1-6 (Regulatory particle Triple A protein), as well as two
organizing subunits; Rpn1 and 2 (Regulatory particle non-ATPase). Two established ubiquitin
receptors - Rpn13 and Rpn10 - are bound to both Rpn1 and Rpn2 [74, 75, 76, 77, 78, 79]. The
AAA-ATPases Rpt1-6 are Mg2+-dependent and share a conserved 230-250 amino acid motif.
They act in the ATP-dependent translocation of protein substrates into the 20S CP. Despite
the strong similarity between them, they are not functionally redundant, and seem to carry
different specificities for proteasome substrates [80, 81, 82]. The lid consists of one constitutive
deubiquitinase (DUB) - Rpn11/POH1 - bound to the non-catalytic Rpn8 subunit, as well as 7
scaffolding proteins: Rpn3,Rpn5,Rpn6,Rpn7,Rpn9,Rpn12 and Rpn15. All but Rpn15 contain a
conserved PCI scaffolding domain at the C terminal, which serves as the contact point between
the subunits. This lends the lid a vaguely hand-shaped structure with Rpn3,7,6,5 and 9 as
the ’fingers’ and the Rpn11 DUB at the centre of the palm, surrounded by Rpn8, 9 and 5. The
constitutive ubiquitin receptor, Rpn10, located in the base, carries a VWA globular domain that
bridges Rpn11 and 9 [83]. In binding, the 19S RP modifies the conformation of the 20S α
N termini, allowing for pore opening and substrate entry, and forming the 26S holoenzyme
complex known as the proteasome.
2.4 Proteasomal degradation of substrates
Ubiquitination alone is not enough to target a substrate for degradation. In addition to carrying
a poly-ubiquitin chain the target protein must also have an unstructured region, that will serve
as the starting point for degradation. The Lys48 ubiquitin chain will bind the proteasome at
one of its several ubiquitin receptors, either the pleckstrin-like domain of Rpn13, one of the two
UIM (ubiquitin interacting motifs) of Rpn10, or the UBA domains found in the shuttle receptors.
This places the unstructured region of the substrate within reach of the AAA-ATPase hexamer
of the 19S base, where it can engage the ATPase motor. ATP hydrolysis leads to conformational
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changes in Rpt1-6, that drive the translocation of the unfolded substrate through the pore
into the 20S CP [84, 85]. Degradation of the substrate occurs progressively as the protein is
unwound starting at the attachment point, while being translocated into the 20S chamber for
proteolysis [86]. The ubiquitin tag is removed as part of this translocation by the proteasomal
deubiquitinases. Multi-ubiquitin chains that have been removed en bloc from their protein
substrate are degraded into monomers by other ubiquitin-specific peptidases in the cytosol,
including Isopeptidase T [29, 87].
Ub UbUb Ub Ub
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Figure 2.3: Steps of the 26S proteasomal degradation cycle.
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2.5 Proteasomal Deubiquitinases
Other proteins also associate with the proteasome, and modify degradation events (Figure 2.4).
This includes the additional shuttle receptors for ubiquitin: Rad23, Ddi1 and Dsk2 (ubiquilins
in mammals). These shuttle receptors have some redundancy with the constitutive ubiquitin
receptors, but show higher specificity for certain subsets of degradation substrates. All three
contact 19S Rpn1 via their N-terminal ubiquitin-like (UBL) domains and bind poly-ubiquitinated
substrates with their C-terminal ubiquitin-associated (UBA) domains [88, 83, 76, 29].
Other 19S associated proteins include the deubiquitinases that carry out the essential re-
moval of poly-ubiquitin chains from the 26S substrates. Removal of the chains replenishes the
cell’s pool of free ubiquitin and allows the protein to be unfolded and translocated into the
proteasome. This chain removal is carried out by proteasomal deubiquitinases that specifically
hydrolyse ester, thiol ester or amide bonds to the Gly76 residue of ubiquitin. The 19S-associated
DUBs consist of the constitutive JAB1-MPN-MOV34 (JAMM) metalloproteinase Rpn11/POH1,
as well as two, more loosely associated, DUBs, UCHL5/uch2/ and USP14/ubp6 (human/yeast
nomenclature). POH1 is a metalloprotease that is thought to be the main source of deubiqui-
tinating activity on the proteasome, while the role of the other two proteasomal DUBS is not
as well understood. While POH1 is an endo-deubiquitinase that shows degradation-coupled
activity, ubiquitin cleavage by UCHL5 and USP14 appears to be independent of degradation.
Both are thought to be exo-deubiquitinases, that cleave the ubiquitin chain form the distal
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end, rather than removing the entirety of it from the substrate protein [89, 90]. This function
may serve in ubiquitin chain editing, but it is uncertain whether these two DUBs function in
promoting or preventing degradation. This ambiguity has been the source of some controversy
in the field of DUB research [89, 91].
2.5.1 Rpn11/POH1
POH1 cleaves the ubiquitin chains at the proximal end in a Zn2+-dependent manner. It is the
only constitutive DUB on the proteasome, and forms an integral subunit of the 19S RP. It is
thought to be regulated in part through conformational changes induced by RP binding to the
20S CP [92, 83, 93], but can also be influenced by the activity of the other two DUBs [94].
It is currently believed that for a ubiquitin chain to trigger degradation of its bound protein
it has to contact both Rpn10 and Rpn13, spanning a distance of ∼ 90Å. This means that a
ubiquitin chain must contain at least 4 ubiquitin moieties in order to successfully target a
protein to the proteasome. The binding of the chain to the proteasomal ubiquitin receptors
then orients the substrate protein in a way that facilitates cleavage of the ubiquitin chain by
POH1, as well as unfolding and translocation. Cleavage of the ubiquitin chain is essential for
degradation to proceed, and loss of DUB activity has been shown to be lethal. At the same time,
deubiquitination by POH1 will only occur in a degradation coupled manner, that is, cleavage
happens once the substrate is committed to degradation[89, 95, 96].
2.5.2 UCHL5
UCHL5 is present in stoichiometric amounts in the 19S subunit, where its C-terminal associates
with that of Rpn13. Rpn13 is in turn associated with the base subunit Rpn2 via its N-terminal.
Binding to Rpn13 has been shown to increase UCHL5 activity, and appears to stabilize the
ubiquitin binding site of the deubiquitinase. UCHL5 is specific for the distal end of poly-ubiquitin
chains, preferring Lys48-linked ubiquitin [97, 98, 99, 100, 101]. It interacts with multiple
residues of the most distal ubiquitin, including Lys48, and may stabilize a salt bridge between
Lys48 and Glu51 within ubiquitin. This interaction limits iUCHL5 binding to the most distal
ubiquitin only, explaining its exo-specificity [102].
2.5.3 USP14
USP14 is the third 19S-associated deubiquitinase, and the main drug target discussed in this
thesis. Like UCHL5, USP14 is associated with the 19S RP in stoichiometric amounts, and is the
most abundant proteasome-associated protein [103]. It binds the Rpn1 subunit in the base of
the RP, via its UBL domain, with a higher affinity than any of the ubiquilin shuttle receptors,
yet it also dissociated easily from the 19S RP. Binding of USP14 to Rpn1 has been shown to
increase its deubiquitinating activity up to 300-fold, while free USP14 appears to have very
little catalytic activity [104, 91, 105].
The structure of the USP14 catalytic USP domain has been reported as a "right hand",
with sub-domains referred to as "fingers", "palm" and "thumb", resembling several other known
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Figure 2.5: The structure and location of the proteasomal deubiquitinase USP14 A) General USP14
structure, with the sub-domains (fingers, palm and thumb) indicated in blue, cyan and purple respectively.
B) Ubiquitin aldehyde (yellow) bound to USP14 (blue) in the ubiquitin binding pocket between the
fingers and thumb sub-domains. C) The location of USP14 (blue) on the 26S proteasome, including
ubiquitin bound to USP14 (yellow) (PDB:2AYO and 5GJQ)
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DUBs (Figure 2.5). The ubiquitin binding site is located between the fingers and the thumb.
The USP14 active site is located between the fingers and the palm. Unlike several other DUBs,
its catalytic triad is already properly aligned prior to substrate binding. However, access to
the catalytic triad is blocked by two loops (BL1 and BL2). Binding of ubiquitin leads to a
conformational change in USP14, which removes several residues that otherwise sterically
restrict access to the catalytic triad. This rearrangement allows the ubiquitin C-terminal to
reach the catalytic site via a cleft connecting the ubiquitin binding pocket to the catalytic
triad (Figure 2.6) [106]. Upon binding to Rpn1 via its Ubl domain, the USP domain remains
somewhat flexible. Association of ubiquitin with the catalytic domain fixes the domain location
in close proximity to the Rpt1 ATPase, bridging the gap between Rpt1 and POH1. This places
the USP catalytic triad in close proximity to both the ATPase active site, and the POH1 DUB,
and suggests a high level of crosstalk between these subunits in order to coordinate proteasome
activation and substrate degradation [103, 107, 94]. The USP14 catalytic triad itself (Figure 2.6)
consists of a catalytic cystein residue (Cys114), histidine (His435) and aspartic acid (Asp451).
The imidazole ring of the catalytic histidine is thought to form a hydrogen bond with the thiol
group of Cys114, an interaction that may be stabilized by Asp451.
Poly-ubiquitin binding by USP14 has been shown to trigger gate opening in the 19S RP,
if it occurs in concert with ATP binding to the 19S RP AAA-ATPases [108]. If USP14 binds
poly-ubiquitin that is associated with a partially unfolded protein substrate, it promotes ATPase
activation, and therefore translocation of the substrate into the 20S catalytic chamber for
degradation [109]. Simultaneously, USP14 has been shown to stabilize the substrate-bound
conformation of the proteasome, while in return the same active proteasome conformation
increases USP14 deubiquitinase activity [94].
The actual role USP14 plays in proteasomal degradation is, however, somewhat contro-
versial. While some have claimed that its primary function is to delay or prevent proteasomal
degradation, others believe that USP14, like POH1 is an instrumental component in enabling
degradation by deubiquitinating proteasomal substrates prior to them entering the catalytic
chamber [110]. There are a multitude of publications in support of either side, which has lead
to USP14 being proposed as a drug target in cancer treatment (inhibiting the proteasome by
USP14 inhibition) [111, 112, 113], as well as a target in the treatment of neurological disorders
such as Huntington’s disease or Alzheimers (promoting clearance of protein aggregates via the
UPS by inhibiting USP14) [114, 115].
In an attempt to unify both sides, some recent publications have suggested that USP14
serves a dual function. According to these proposals, non-ubiquitin-bound USP14 suppresses the
basal peptidase activity of the proteasome, while ubiquitin-bound USP14 increases proteasomal
ATPase activity, substrate translocation and degradation. Moreover, blockage of the 20S catalytic
activity, and build-up of poly-ubiquitinated protein substrates quickly increases the association
of USP14 with the proteasome, while absence of poly-ubiquitin will cause rapid dissociation
[107, 116]. Similarly, inhibition of USP14 using ubiquitin aldehyde, or other ubiquitin-based
active site inhibitors, leads to increased binding of USP14 to the proteasome [104]. It has been
suggested that this mechanism serves to encourage proteasomal selectivity for ubiquitinated
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Figure 2.6: The catalytic triad (red) of USP14 (blue) consisting of Cys114, His435 and Asp451. The
ubiquitin (yellow) C-terminal has access to the catalytic triad for cleavage (PDB:2AYO).
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proteins, if such proteins are present [107, 116].
The role of USP14, and its use as a drug target will be discussed further later in this thesis.
However, a considerable body of evidence- including our own data- indicates that removal or
inhibition of USP14 is a trigger for proteotoxic stress.
2.6 Proteotoxic stress and Proteostasis
Proteasome overload, dysfunction, or inhibition has detrimental effects on cell health and
survival. Maintenance of proteostasis is therefore a key process in any cell. Previous research
has shown that it may be especially important in cancer cells that produce high amounts of
unfolded or mutated protein, which are therefore described as having a non-oncogenic addiction
to proteasomal degradation [117, 118]. Proteasome inhibition has been shown to severely upset
cellular proteostasis, leading to apoptosis via an increase in ER stress, accumulation of reactive
oxygen species (ROS) and mitochondrial damage [119, 120, 121].
ROS, including hydrogen peroxide, as well as superoxide and hydroxyl radicals are a byprod-
uct of oxidative metabolism in mitochondria. In healthy cells, ROS levels are maintained by an
antioxidant system that prevents oxidative damage to proteins and organelles, while oxidized
proteins are degraded by the proteasome [122, 123]. Proteasome inhibition has been shown to
induce both ER stress and mitochondrial damage, both of which cause an increase in cellular
ROS levels, compounding the existing proteotoxic stress the cell is experiencing. Since the
direct cytotoxic effects of ROS are somewhat debatable [124], the role of ROS in apoptosis
via proteasome inhibition is uncertain. However, it has been shown that proteasome inhibition
leads to mitochondrial membrane depolarization [125], thereby triggering a mitochondria-
dependent caspase cascade, culminating in apoptosis [126, 127]. Cells possess several partially
redundant mechanisms to protect themselves against proteotoxic stress and ensure their con-
tinued survival. These mechanisms include autophagy, the ER stress response, and aggregate
formation, and are summarized in Figure 2.7.
2.6.1 ER stress
The endoplasmic reticulum (ER) is the first step in the cellular secretory pathway that manages
synthesis, modification and delivery of proteins within the cell [128, 129]. There is evidence
of extensive crosstalk between the UPS and the ER [130, 131], and proteasome inhibition is a
known inducer of ER stress [132, 120, 133].
Nascent unfolded proteins, are translocated into the ER for processing. This involves the
folding or re-folding of protein chains, as well as disulfide bond formation. Folding is managed
by various ER molecular chaperones, prior to shipping of the folded protein to the Golgi, or other
intracellular compartments via vesicles [134]. The protein folding pathway is highly conserved
from bacteria to mammals [129]. ER stress describes the event when the folding capacity of the
ER becomes overloaded, i.e. the volume of unfolded protein within the ER becomes too high.
This can occur due to a variety of cellular stresses, including thermal stress, mutations, hypoxia
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or infection [135, 132]. Proteasome inhibition will increase the concentration of unfolded
protein outside the ER, yet triggers the ER stress response. This may be due to increased calcium
levels as a result of proteasome inhibition, or due to the interaction of unfolded protein with
cytosolic chaperones [136, 137, 138, 139].
In the event of ER stress, the Unfolded Protein Response (UPR) is activated. Three trans-
membrane proteins manage the UPR in mammals: the kinases IRE1 and PERK, and the tran-
scription factor ATF6 [140, 133]. These proteins are located in the ER membrane, with a
stress-sensing domain facing the ER lumen, and a functional domain facing the cytosol. The
ER-internal domain is bound to BiP, a heat-shock protein 70 (Hsp70). BiP has a high affinity
for hydrophobic patches on unfolded proteins. In the presence of unfolded proteins in the ER
lumen it will dissociate from the domains of the three transmembrane proteins, allowing them
to activate and trigger the UPR [140, 141, 142]. The UPR has two main functions: reducing
the folding demand in the ER, and increasing the ER folding capacity [135]. However, pro-
longed activation of the UPR will trigger cell death [143, 144], thus the UPR will activate both
pro-survival and pro-death functions [145].
Both IRE1 and ATF6 modulate increased transcription of chaperones to increase the ER’s
protein folding capacity [146, 147]. In order to reduce ER folding demand the UPR will down-
regulate protein translation, and upregulate ER-associated degradation (ERAD). Translation is
downregulated via PERK-mediated phosphorylation of eIF2α. As a component of the translation
pre-initiation complex eIF2αmust bind GTP in order to facilitate recognition of the mRNA start
codon. Phosphorylation at Ser51 by PERK prevents nucleotide exchange, thereby preventing
translation initiation [148, 149, 150, 151, 152]. PERK also phosphorylates Nrf2, as part of its
second pro-survival function, in order to increase glutathione levels - an antioxidant that will
combat the increase in reactive oxygen species (ROS), associated with ER stress [153].
ERAD is primarily activated by IRE1-mediated splicing of XBP1 mRNA - a highly active
transcription factor that is controlled by ATF6 [147, 154]. Like the rest of the UPR, ERAD
depends on the activity of ER chaperones, that bind the unfolded protein in the ER lumen
[142]. ERAD will effect the removal and extraction of unfolded protein from the ER, and deliver
them to the proteasome for degradation [155, 156] in a process called retrotranslocation or
dislocation. This reduces the ER’s folding load. ERAD substrates are recognized and bound by
Hsp chaperones (Hsp40, Hsp70 or Hsp90), which will then recruit the E3 ligase CHIP. How
exactly the protein substrates are removed from the ER is currently not fully understood. A
putative protein channel termed the dislocon is thought to be responsible for the transport,
which seems to be both ATP- and ubiquitin-dependent. Several E3 ligases are responsible for
ubiquitinating the protein substrates as they emerge for the ER [157, 158, 159]. The AAA-
APTPase p97/VCP has been reported as not only a main regulator of proteostasis [160], but
also the primary linkage between ERAD and the UPS [161]. VCP is required for the extraction
of unfolded protein from the ER, as well as other organelles including mitochondria. In the
case of ERAD activation, p97/VCP is recruited to the ER membrane, where it associates with
the ER-bound E3 ligase Hrd1. Hrd1 ubiquitinates emerging ERAD substrates and causes them
to be targeted to the proteasome [162]. VCP then forms a complex with the ubiquitin-binding
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proteins Np14 and Udf1 to bind the ubiquitinated ERAD substrates and deliver them to the
proteasome, with the help of proteasome shuttle receptors such as Dsk2 and Rad23 [163, 156,
164].
2.6.2 Aggregate formation
The accumulation and aggregation of misfolded or damaged proteins is a common occurrence
in any cell [165], and is tightly linked to ER-stress, proteasomal degradation and autophagy.
Protein accumulation can be induced by changes in protein structure due to mutations, thermal
stress and oxidative stress, as well as some types of viral infections, which will lead to ER stress,
resulting in ERAD and increased cytosolic levels of unfolded protein [166, 167]. These proteins
would normally be targeted to the proteasome for degradation and clearance [22, 6].
In the event of insufficient proteasome activity, such as in severe cases of ER stress, pro-
teasome inhibition, or oxidative stress, poly-ubiquitinated unfolded proteins must be removed
from the cytosol. To this end, these proteins are trafficked along the microtubule network
to form a single large inclusion body at the microtubule-organizing center (MTOC) in close
proximity to the nucleus [168, 165]. This inclusion body is referred to as an aggresome.
Aggresomes have been found to contain not only poly-ubiquitinated protein, but also several
chaperones, especially HSPs, which are known to be upregulated in cells as a first line of
defense against proteotoxic stress [169]. Aggresomes also contain components of the USP,
such as proteasomal subunits, as well as various adapter proteins that act in the aggregation,
segregation and the eventual autophagic clearance of aggresomes. The process of aggresome
formation and clearance is fairly complex and not throughly understood. It involves interaction
of the substrate proteins with several enzymes, including p97/VCP, SQSTM1/p62 and HDAC6,
as well as motor proteins and the cytoskeleton [170, 171].
The AAA-ATPase VCP/p97 facilitates the extraction of unfolded proteins from the ER during
ERAD, and then further controls the transport of these proteins towards the proteasome [162].
In the event of a proteasomal defect, cells may upregulate the histone deacetylase HDAC6. This
unique deacetylase contains a C-terminal zinc-finger motif that allows it to bind to ubiquitin
chains with high affinity [171, 172]. HDAC6 also contains a dynein-binding domain that allows
it to link unfolded protein to dynein motors on the cytoskeleton for transport to the aggresome
at the MTOC [169]. Aggresome formation is therefore dependent on cytoskeletal integrity.
While the temporary accumulation of poly-ubiquitinated protein in the aggresome removes
potentially harmful aggregates from the cytoplasm [173, 174], this is only a temporary solution
to proteotoxic stress. Aggresome formation is thought to facilitate the autophagic clearance of
toxic protein aggregates, by creating a single locus for the recruitment of autophagic machinery
[175]. There is a strong body of evidence suggesting that SQSTM1/p62 is the main link between
aggresome formation and autophagic clearance of aggregates [176, 177]. SQSTM1/p62 is a
stress induced scaffold protein that serves as the main adapter protein in autophagy [178].
Additionally p62 appears to actively promote aggregation of poly-ubiquitinated proteins in the
cytosol by forming p62 filaments when bound to poly-ubiquitin chains [179], thus linking the
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poly-ubiquitinated proteins into larger clusters.
2.6.3 Autophagy
Autophagy is the second major pathway of protein degradation in cells after the UPS. While the
UPS is mostly responsible for the dynamic degradation of short-lived and soluble proteins, as
well as ERAD substrates, autophagy primarily targets non-soluble, long lived proteins, as well
as protein aggregates and entire organelles for degradation [180]. Autophagy is a a lysosome-
dependent pathway, in which degradation is carried out by a large specialize organelle, called
the autophagosome [181]. Autophagic degradation can be divided into two sub-categories :
Unselective autophagy, and selective autophagy. Unselective autophagy has the primary func-
tion of cellular nutrient recycling and maintaining homeostasis [182], which protects the cell
from stress and disease [183]. Selective autophagy targets specific proteins.
Initially thought to be an entirely non-specific pathway for degradation, autophagy has
now been shown to be capable of specifically targeting substrates, as well as having significant
crosstalk with the UPS [184, 185]. Like UPS-dependent degradation, selective autophagy is de-
termined by ubiquitin labeling of the substrate - primarily unfolded protein. The ubiquitinated
proteins are then targeted by sequestrome 1 (p62/SQSTM1) [186] and other autophagy-related
proteins, such as HDAC6 [187] and HSPs [188]. These proteins recruit autophagic machinery
to the site of the unfolded protein, and promote clearance [189, 188]. The process of autophagy
consists of four distinct steps: induction, cargo recognition and selection, autophagosome for-
mation, and fusion of the autophagosome with the lysosome. Inside the lysosome the cargo is
then degraded and its components are released into the cytosol [190].
The autophagic response can be initiated via ERAD, in response to ER stress. It also serves
as a redundancy mechanism in case of proteasome dysfunction or inhibition [133, 191]. Au-
tophagic clearance is the primary mechanism of aggresome removal after proteasome inhibition,
thus promoting cell survival [192]. The sequestrome 1 protein p62/SQSTM1 is the primary link
between UPS-mediated degradation and autophagy. Recent publications have shown that p62
is an essential component of the aggresome-formation mechanism that clears misfolded protein
from the cytosol in the event of proteasome overload or dysfunction [176, 179, 193]. It also
serves as a ubiquitin-binding adapter protein in autophagy. This allows the aggregates to then
function as signaling nodes to promote autophagic clearance, modulated by p62 [178, 194].
Additonally, p62 is an important component of the Keap1-Nrf2 signaling pathway. Under
normal conditions p62 is poly-ubiquitinated by the Keap1-Rbx1 E3 ligase complex, targeting it
for autophagic degradation. In the event of proteotoxic stress it becomes phosphorylated at its
Ser349 residue- This allows p62 it to interfere in the ubiquitination of the transcription factor
Nrf2 by Keap1. Once stabilized, Nrf2 translocates to the nucleus, where it activates transcrip-
tion of autophagy-associated genes, antioxidants and p62 itself [178, 195].
Put simply: Cells can employ the above responses in an attempt to correct conditions of
proteotoxic stress. The ER stress response will increase the ER folding potential, while targeting
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excess unfolded protein to the proteasome. VCP will extract proteins from the ER and functions
in trafficking them to the proteasome. In the event of proteasome dysfunction, it will pass the
unfolded protein substrates on to HDAC6 for trafficking to the aggresome, where p62 is involved
in recruiting autophagic machinery for aggregate clearance. These processes serve to protect
the cell from cytosolic protein toxicity. However, none of these responses are a sustainable
solution, and prolonged proteotoxic stress will eventually force the cell to undergo apoptosis.
2.6.4 Cell Death
Proteotoxicity-induced apoptosis can be triggered in a variety of ways. It has been shown that
apoptosis induced by proteasome inhibitors is primarily effected via ER stress or mitochondrial
damage [196, 143, 197], as well as the increased levels of cytosolic pro-apoptotic proteins, such
as p53, as well as p27Kip1 and p21Cip1, which will cause cell cycle arrest in the G2/M phase
[198]. Increased levels of p53 will lead to upregulation of pro-apoptotic proteins, including
Bax, and will lead to cell cycle arrest and apoptosis [199].
Prolonged ER stress will result in ER-activated autophagy (ERAA) and apoptosis by upreg-
ulating the pro-apoptotic transcription factor ATF4 (activating transcription factor 4), which
in turn activates transcription of CHOP (C/EBP homologus protein) and GADD34 (Growth
Arrest and DNA-damage inducible gene 34). CHOP induces transcription of TRAIL-R1/DR4
and TRAIL-R2/DR5 [200, 201, 202], which mediate caspase-8-dependent apoptosis [203, 204].
It also causes the translocation of the pro-apoptotic protein Bax to the mitochondria, triggering
mitochondria-dependent apoptosis via caspase 3 [205, 197]. GADD34 recruits protein phos-
phatase 1 (PP1) to the ER, where it will dephosphorylate eIF2α, reversing the translational
repression that was part of the initial ER stress response [206]. IRE1 activation by ER stress will
lead to the activation of JNK (c-Jun N-terminal Kinase), as well as caspase 4 [207]. JNK phos-
phorylates the anti-apoptotic protein Bcl-2, interfering with its binding and inhibition of the
pro-autophagy Beclin 1. Active Beclin 1 is a component of the PI3K-III (class III phosphatidyli-
nositol 3-kinase) complex, which is responsible for the recruitment of autophagy machinery
and membrane components [208, 209], thus triggering autophagy. Additionally active JNK can
translocate to mitochondria, where it will stimulate the release of cytochrome c from the inner
mitochondrial membrane. This process is dependent on pro-apoptotic Bid and Bax, and initiates
the activation of caspase-9-dependent caspase cascade, culminating in apoptosis [210].
A delay in autophagic clearance of aggresomes has been shown to lead to DNA damage and
p53-mediated cell cycle arrest [211]. It has been found that agents which disrupt aggresome
formation, such has HDAC6 inhibitors, synergize with proteasome inhibitors in the induction
of cytotoxicity in cancer cells [212, 213], consistent with the idea that aggresome formation
has a cytoprotective function [214, 215, 216, 217, 218, 219].
Strategies that inhibit aggresome formation, to enhance cytotoxicity induced by established
proteasome inhibitors, such as bortezomib, have been generating increased interest in recent
years [213, 220]. Given the dependence of many cancer cells on efficient proteasomal degra-
dation and ROS management, targeting these processes is a popular strategy in cancer drug
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development. Compounds that trigger ER stress are being investigated for potential adjuvant
use with proteasome inhibition. Inducing or increasing proteotoxic stress, or interfering with
the compensatory mechanism cells can use to alleviate proteotoxic stress, as a means to rapidly
induce commitment to apoptosis, are also an appealing potential method of targeting cancer
cells [221, 222, 223].
2.7 The UPS in Cancer and Disease
Due to its vital functions in a multitude of essential cellular processes, UPS malfunction has been
implicated in the pathogenesis of a broad rage of diseases, including cystic fibrosis, immune
dysfunction and muscle wasting disorders [28]. The most prevalent of the diseases involving
the UPS are neurodegenerative disorders and cancer. The UPS involvement can be explained
by either a loss of function of degradation, or a gain of function.
Loss of function, leading to stabilization and accumulation of proteasome substrates, is
of primary importance in neurodegenerative disorders, such as Alzheimer’s and Huntington’s
disease. Gain of function, where substrates are degraded at an accelerated rate, is relevant in
cancer development, as will be described in detail [9, 24].
2.7.1 The UPS in Neurodegeneration
Several neurodegenerative diseases including Huntington’s Disease, Alzheimer Disease, and
Parkinson’s, involve abnormal protein aggregates and inclusion bodies. Theses aggregates have
been shown to include both poly-ubiquitin and proteasomes, implicating a dysfunction of
protein degradation, where the substrates are labelled for degradation, but not removed [9,
224]. While proteasome impairment may be part of the underlying cause for neurodegenerative
disorders, protein aggregates have in turn been shown to inhibit proteasome function. Amyloid
β plaques may inhibit all three catalytic activities of the 20S CP. A clear link between the UPS and
neurodegeneration has yet to be established, but work is under-way to employ enhancement
of proteasomal degradation as a treatment strategy in a variety of disorders [50].
2.7.2 The UPS in Cancer
In cancer, UPS activity and dysfunction play a major role, which is not surprising considering
how many cellular processes are regulated via protein degradation. The UPS and its regulation
are especially important in cell cycle progression and cell death induction; processes that require
the specific and well-timed removal of various active proteins [26]. Components of the UPS
are therefore common targets of oncogenic mutations [25]. Frequent sites of these mutations
are various E3 ubiquitin ligases or their components. Examples include the E3 component
VHL, which is involved in degradation of hypoxia-induced transcription factors (HIFs). VHL
is known to be a gatekeeper mutation in renal clear cell carcinoma, as its loss of function
prevents HIF degradation, leading to a hypoxia response under normoxic conditions - inducing
angiogenesis and promoting tumor growth [225, 226]. The breast-cancer type 1 susceptibility
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protein BRCA1 is also known to carry E3 ligase activity [227]. While its exact function as an
E3 ligase is not fully understood, it is known that mutations in the BRCA1 Zn2+-binding region
- which is responsible for its ubiquitin ligase activity - predispose to breast cancer development
[228].
Various oncogenes and tumor suppressors are also degraded via the UPS. This includes the
cell cycle regulators p53 and p27Kip1. The p53 tumor suppressor is a main component of cellular
stress response, and is responsible for inducing cell cycle arrest, senescence and apoptosis in
response to DNA damage [229, 230, 231]. The cellular levels of p53 are regulated by the MDM2
E3 ligase, which targets p53 to the proteasome for degradation [232]. Amplification of MDM2
is commonly found in p53-wt cancers, where it reduces p53 levels and allows for unchecked
cell cycle progression [233]. Several high-risk strains of of human papilloma virus (HPV) take
advantage of this pathway. The viral HPV E6 protein will bind to the cellular E6-AP E3 ligase.
The resulting dimer then ubiquitinates p53, targeting it to the proteasome [234, 235, 236].
The cyclin-dependent kinase inhibitor p27Kip1 is also a proteasome substrate, and can be down-
regulated by the UPS [237, 238, 239]. Down-regulation of p27Kip1 occurs in various cancers,
where it correlates with poor prognosis [240, 241, 242].
Other oncogenes targeted by the UPS include c-Myc, n-Myc, Jun, and cyclin E [21]. At
the end of each mitotic cycle, cyclin-specific E3 ligases target cyclins for destruction by the
proteasome [243]. Aberrant levels of cyclin E have been shown to correlate with poor prognosis
and survival in several types of cancer, leading to tumor formation, chromosome instability and
cell cycle dysregulation [244, 245, 246].
Various deubiquitinases have also been implicated in cancer initiation and progression.
This includes both of the 19S-associated deubiquitinases, USP14 and UCHL5, which have been
found to be overexpressed in a range of cancer types, and are associated with less favorable
prognoses[247]. Inhibition of these two proteasomal DUBs has been shown to have cytotoxic
effects in a range of malignancies [248, 249, 111].
Proteasome activity has been shown to be increased in many cancers. This may be due to
higher levels of protein translation as a result of aberrant proliferation rates. Other contributors
are elevated oxidative stress, production of mutant proteins, as well as frequently increased
levels of exposure to cytokines and growth factors, experienced by cancer cells [118]. In fact,
the reliance of many cancer cells on UPS-mediated protein degradation has in recent years been
described as a type of non-oncogenic addiction [117]. Accordingly, proteasome inhibition has
been shown to slow or block cancer growth and angiogenesis in a variety of cancer models [250].
Additionally UPS inhibition can stabilize the levels of tumor suppressors, including p53 and
p27Kip1, curbing unchecked cell division [251]. Its central role in essential cell processes and
the common reliance of cancer cells on rapid protein degradation make the UPS an attractive
therapeutic target in cancer therapy [9, 50, 252, 253].
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2.8 Targeting the UPS in Cancer Treatment
The idea to target the UPS in the treatment of various disorders, and either enhance or inhibit
its function, depending on the desired effect, has been under investigation for several years
[254, 255]. Especially the development of UPS inhibitors, targeting an array of components
of the ubiquitin-proteasome system, has been a focal point of extensive research in recent
years. Additionally the development of proteasomal DUB inhibitors has generated increasing
interest [256]. Potential targets within the UPS are abundant, and research has been done on
a multitude of its components. The most promising targets include E3 ligases, the 20S catalytic
core and the 19S regulatory particle.
2.8.1 Targeting the ubiquitin cascade
Inhibitors have been developed for each step of the ubiquitination pathway, targeting E1, E2 and
E3 enzymes. Due to their high specificity and the almost 600 known E3 ligases, they may be the
most promising, as they provide the most targeted option for intervention. Several E3 ligases
have no conserved active site, making targeting challenging, especially of HECT type E3 ligases.
The E3 inhibitors that are in development primarily target RING- type E3’s, by preventing the
association of their several subunits, or by preventing substrate binding [257]. Examples are
RITA and MI-219, two compounds that target the MDM2/HDM2 (mouse/human) E3, which
specifically ubiquitinates p53. Preventing HDM2-p53 association stabilizes p53, allowing for
p53-mediated cell cycle arrest and apoptosis to proceed [258]. Another promising target in
cancer therapy are the IAP (Inhibitors of Apoptosis) family, which contain several RING E3
ligases [259]. IAPs are frequently found to be upregulated in cancer, promoting cancer cell
survival by inhibiting caspase activation and apoptosis. IAP inhibition with RITA or nutlin
compounds allows the caspase cascade to proceed and leads to apoptosis [257, 260, 261].
Another method of inhibiting the ubiquinating machinery is by directly targeting ubiquitin
chains, and preventing their association with the proteasome. Several compounds, termed ubis-
tatins, can achieve this by binding the ubiqitin-ubiquitin interface of K48-linked poly-ubiquitin
chains, preventing recognition of the chains by the protasomal ubiquitin receptors. This is a non-
specific approach that prevents the degradation of a broad spectrum of cell cycle components
and regulators, including cyclin B and p53, and leads to cell cycle arrest [257, 262, 263].
2.8.2 Targeting 20S
Targeting the 20S catalytic core particle inhibits total protein degradation in the cell. While
this approach is broader than inhibition of specific E3 ligases, it has shown promising effects in
the clinic. While the early generation 20S inhibitor MG132 is quite potent and of considerable
use in in vitro experiments, it displayed instability in vivo [264]. The primary example of a
20S inhibitor with clinical application is the peptide boronate bortezomib, the first proteasome
inhibitor to be approved by the FDA [265].
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Bortezomib
The 20S inhibitor bortezomib (Velcade®/ PS-341) is a boronic acid dipeptide [266] that tar-
gets the catalytic β5 subunits of the 20S CP, inhibiting the chymotrypsin activity in a reversible
manner [267, 268]. It has a biological half-life of about 24h [269] and has been shown to
stabilize proteasome substrates including p53 and p27Kip1, as well as pro-apoptotic members
of the Bcl-2 protein family, leading to apoptosis [270]. The structure of bortezomib is shown
in Figure 2.8. The apoptotic effect of bortezomib has been primarily attributed to its induc-
tion of increased levels of the pro-apoptotic protein NOXA, as well as an inhibition of NFκB
signaling [207], a response that is characteristic of proteasome inhibition [251]. This method
of targeting the proteasome has been shown to be more effective in cancer types that display
increased protein synthesis and ER stress. Examples include multiple myeloma as well as man-
tle cell lymphoma, which characteristically show amplified synthesis of proteins, especially
immunoglobulins [271]. In clinical use, bortezomib elicited a good response in 48% of new
patients, and a 35% response rate in patients with relapsed and refractory multiple myeloma
[266]. However, resistance to bortezomib is a common occurrence, either through mutation or
overexpression of the β5 subunit [272, 273, 274] or protective mechanisms mediated by HSPs
[275]. An additional resistance mechanism may involve the overexpression of mutant Bcl-2
protein. It has been shown that myeloma and lymphoma cells that express Bcl-2 mutants with
a higher affinity for NOXA display resistance to the pro-apoptotic effects of increased NOXA
levels. Further difficulties in the clinical use of bortezomib stem from dose-limiting toxicity
issues and interactions with some natural compounds [207].
As the first FDA-approved inhibitor of the UPS, bortezomib has however inspired further
research into alternative methods of proteasome inhibition, leading to the discovery of a whole
range of other compounds that are currently under development.
Next generation 20S inhibitors
The second generation 20S inhibitor Carfilzomib (Kyprolis®) is an epoxyketone, based origi-
nally on the drug epoxomicin [278] (Figure 2.8). It irreversibly targets the same binding site
on the β5 subunit as bortezomib, and demonstrated overall higher specificity and activity than
bortezomib [279, 280]. Carfilzomib has been FDA approved as a treatment in relapsed and
refractory multiple myeloma [281]. However, it has been shown that resistance to bortezomib
also decreases the efficacy of carfilzomib, suggesting that this second-generation inhibitor is
vulnerable to acquired resistance by the same mechanism as bortezomib [282].
Other second generation 20S inhibitors include the epoxyketone oprozomib, as well as the
reversible boronic acid inhibitors delanzomib and ixazomib. All of these inhibitors are primarily
intended for use in multiple myeloma, and all are potent cytotoxic compounds [280]. Much
like bortezomib, promising anti-neoplastic effects were primarily observed in hematological
malignancies, while results for 20S inhibitors in solid tumors have been mostly discouraging
[207].
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Figure 2.8: The 20S inhibitors A) Bortezomib and B) Carfilzomib [276, 277]
2.8.3 Targeting 19S
The most promising targets located on the 19S RP are the ubiquitin receptors within the lid,
and the 19S-associated deubiquitinases. Ubistatins (A and B) have been successfully used to
inhibit ubiquitin chain binding to the proteasome ubiquitin receptors. These compounds bind
to the Ub-Ub linkage in Lys48 ubiquitin chains, preventing recognition by the receptors [262].
The RA-190 compound is reported to target the constituitive 19S ubiquitin receptor Rpn13,
preventing ubiquitin binding and substrate degradation [283], which has shown anti-cancer
potency in multiple myeloma cell models [284, 285].
The proteasomal deubiquitinases USP14 and UCHL5 can be inhibited by several compounds,
including the small molecule inhibitor b-AP15, causing accumulation of proteasomal substrates
and poly-ubiquitin, eventually leading to cell death [111]. The following sections will focus on
targeting these two proteasomal deubiquitinases in cancer treatment in more detail.
2.9 Targeting 19S Deubiquitinases in Cancer Treatment
Both USP14 and UCHL5 have been reported to show increased expression in a variety of cancers
[286], where they are frequently associated with worse prognoses and survival [112, 113]. Thus,
the 19S DUBs have garnered increasing interest as potential drug targets in cancer therapy
[111, 256]. Inhibition of USP14 has been shown to be an effective method of intervention in
several types of cancer, including squamous cell carcinoma [287], multiple myeloma [288],
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melanoma [289], Waldenström macroglobulinaemia [290, 291], and colorectal cancer [249].
Targeting DUBs has been technically simpler than targeting E3 ligases, partially due to their
lower diversity, and the conserved cysteine residues found in the majority of deubiquitinases.
USP14 and UCHL5 both contain conserved active site cysteines. The reactivity of cysteines lends
itself to effective targeting using electrophilic compounds. POH1, however, is a metalloprotease,
which is can be targeted by zinc-chelators such as thiolutin [292], but generally is not sensitive
to the same compounds that will bind to the other two proteasomal DUBs. This makes it possible
to develop compounds that target USP14 and UCHL5 only, without risking the general cytotoxic
effects of POH1 inhibition.
The use of electrophilic compounds can be problematic due to general reactivity within the
cell, that can result in proteasome-independent cytotoxicity, and may prevent achieving high
specificity for particular DUBs [293, 113]. Yet, recently significant advances regarding DUB
targeting and function have been made. An array of compounds has been developed that target
both USP14 and UCHL5 deubiquitinases with varying degrees of specificity, some of which
show a high degree of promise [113, 294, 256, 295, 296].
2.10 Deubiquitinase Inhibitors
Established proteasomal deubiquitinase inhibitors include an array of natural compounds as
well as synthesized derivatives and novel molecules. The idea that an α,β -unsaturated ketone
motif (or enone) is the essential component of certain types of DUB inhibitors has been estab-
lished and explored over the course of the last two decades [296]. Unsaturated ketones are a
common feature of many DUB inhibitors that have been developed, while others function by
alternative mechanisms that frequently target the DUB catalytic cysteine.
2.10.1 Curcumin
The yellow plant extract curcumin (tumeric, Figure 2.9) has long been used in traditional
medicine. Curcumin has validated anti-tumor effects, as well as known benefits for a wide
range of other disorders. It is one of the most widely studied anti-tumorigenic compounds
today [297, 298]. Curcumin’s broad range of effects is most likely due to the inhibition of
proteasomal activity, and the resulting accumulation of poly-ubiquitin, followed by cell death
in sensitive cells. However, its exact mechanism of action is unknown. Its structure, featuring
an α,β-unsaturated ketone group, may target reactive conserved cysteines found in DUBs
[299], preventing proteasomal deubiquitination, and effectively blocking protein degradation.
However, direct effects on the 20S CP have also been described. 19S DUB inhibition may
therefore only be a contributing factor to the anti-neoplastic activity ascribed to curcumin.
Curcumin has been shown to be effective in cancer treatment, despite fairly poor bioavail-
ability [300, 301, 302, 113]. Other natural compounds that likewise carry an α,β -unsaturated
ketone have been shown to have broad range anti-DUB activity, and also target UCHL5 and
USP14. This includes betulinic acid and gambogic acid, both also known in traditional medicine
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[303, 304].
Figure 2.9: Chemical structure of curcumin, indicating the α,β -unsaturated ketone motifs in blue [305,
298]
2.10.2 AC17
The 4-arylidene curcumin analogue AC17 follows a similar mode of action, also carrying an
α,β-unsaturated ketones, allowing it to target USP14 and UCHL5 irreversibly. This has been
shown to lead to inhibition of protein degradation without blocking the 20S proteolytic activity
(unlike curcumin, which also targets proteolysis). AC17 treatment results in accumulation of
poly-ubiquitin, as well as inhibition of the NFκB pathway and stabilization of p53, cumulating
in apoptosis [306]. More recently, several additional 4-arylidene curcumin analogues were
reported as potential 19S DUB inhibitors, all of which feature the same α,β -unsaturated ketone
motif [307].
2.10.3 WP1130
Another DUB inhibitor with reported anti-tumour activity is the small molecule WP1130, which
has been shown to have broader inhibitory functions, targeting USP9x and USP5 along with
USP14 and UCHL5. Similarly to the previously described compounds it results in apoptosis of
malignant cells via poly-ubiquitin accumulation and increase of pro-apoptotic proteins [308] as
well as activation of the unfolded protein response [309]. Research suggests that the anti-cancer
effects of WP1130 are primarily due to its inhibition of USP9X, resulting in the proteasomal
degradation of various anti-apoptotic proteins including c-Myc and Bcr/Abl [310, 311]. The
unsaturated ketone motif can be found here too. However, WP1130 only carries a single one.
2.10.4 Auranofin
The gold-containing compound auranofin was originally FDA approved as a treatment for
rheumatoid arthritis, and has since been repurposed for applications in immunosuppression,
and cancer treatment [313]. Auranofin has been shown to induce cellular proteotoxicity as well
as inhibition of USP14 and UCHL5, resulting in proteasome-blockage and toxicity to cancer
cells. However, USP14 inhibition only occurs at concentrations exceeding IC50 [316]. It has
been suggested that an intermediate form of the compound allows the chelated gold ion (Au+)
to directly target the USP14 and UCHL5 catalytic triads [312].
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Figure 2.10: Chemical structures of a range of established 19S DUB inhibitors. If present, unsaturated
ketones are indicated in blue [306, 308, 312, 313, 314, 315, 114]
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2.10.5 Metal pyrithiones
Along with auranofin, several metal containing compounds have recently gained the spotlight as
potential 19S DUB inhibitors. One focus has been on metal pyrithiones - chelating complexes of
metal ions- such as copper pyrithione (CuPT), cadmium pyrithione (CdPT) and zinc pyrithione
(ZnPT). Both CuPT and ZnPT have previously known properties as anti-fouling components in
paint and anti-dandruff agent respectively [317, 318]. Recent research has revealed that these
metal pyrithiones are potent UPS inhibitors that lead to the accumulation of poly-ubiquitin, and
caspase-dependent cell death in cancer cell lines, primary tumor cells and xenograft models
[314, 319, 318]. All three have been shown to target USP14 and UCHL5, leading to UPS
inhibition. CuPT and CdPT also display 20S inhibitory properties at higher concentrations. As
with auranofin, a potential docking mechanism suggests that a metal-containing intermediate
form of the chelating complex interacts directly with the catalytic triad of USP14 and UCHL5
[318, 313].
2.10.6 G5/2c
The research and increased awareness of the phamacological properties of α,β-unsaturated
ketones [296] was put to a targeted use in the development of the bis-arylidenecycloalkanone
isopeptidase inhibitor G5 [320], and later its derivative 2c [321]. The 2c compound, tagged
with biotin, was successfully used as bait to isolate possible targets of these types of molecules,
which the group termed Partially Selective Isopetidase Inhibitors (P-SIIs) [315]. A pull-down
screen revealed targeting of the DUBs USP1, USP18, USP14, UCHL5 and USP33. An additional
mass spectrometry screen indicated targeting of several other proteins, some of which are also
involved in cellular proteostasis.
2.10.7 IU1 and the USP14 controversy
The USP14-selective inhibitor IU1 was first described in 2010 by a group working on the premise
that USP14 and its yeast homologue UBP6 inhibit proteasomal degradation [110, 114]. While
in yeast the inhibitory effects of UBP6 were of an allosteric nature, it appeared that USP14-
dependent proteasomal inhibition in humans was dependent on its catalytic activity. Following
this reasoning, an inhibitor of USP14 catalytic activity would have potential applications in
treatment of neurodegenerative diseases, where it could increase the removal of aberrant
proteins. IU1 was the result of a drug-screen with the objective of finding such an inhibitor. It
was reported to reversibly inhibit USP14 catalytic activity at an IC50 of 4-5µM, and the ability
to increase degradation of tau and TDP-43 in vitro and in cells [114]. IU1 was not reported to
induce apoptosis.
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2.11 b-AP15 as a DUB inhibitor
Targeted inhibition of USP14 has been achieved with the DUB inhibitor b-AP15. This small
molecule has been shown to specifically bind USP14 and UCHL5, although showing higher
affinity for USP14. It has no visible activity in a panel of other DUBs, and specifically inhibits
USP14 at pharmacological concentrations of 1µM, without inhibition of related deubiquitinases.
Additionally, b-AP15 treatment did not decrease total cellular DUB activity [322, 323, 111].
2.11.1 b-AP15 structure
The b-AP15 compound also contains the commonly observed α,β-unsaturated ketone. This
motif contains two Michael acceptors - electrophilic groups that are thought to target reactive
cysteine residues, such as the catalytic cysteine in the active site of both USP14 and UCHL5.
Despite being a covalent modification, b-AP15 inhibition has been shown to be reversible.
However the commitment to apoptosis induced by b-AP15 is irreversible. This inhibitor has been
shown to have anti-neoplastic effects in a variety of malignancies including acute lymphoblastic
leukaemia, multiple myeloma, and Waldenström macroglobulinemia [323, 324, 291].
Figure 2.11: The structure of the small molecule inhibitor b-AP15 and its derivative VLX1570. The
unsaturated ketones characteristic of these molecules are indicated in blue.
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2.11.2 b-AP15-induced proteotoxicity
Treatment of cancer cells with b-AP15 induces the accumulation of poly-ubiquitin, as seen with
other inhibitors of proteasomal DUBs as well as the 20S CP, however, apoptosis induced by
b-AP15 is independent of both p53 and Bcl-2 status of the cells. Since both of those factors
strongly influence bortezomib sensitivity, b-AP15 may have an advantage in terms of appli-
cability. Additionally, b-AP15 cytotoxic effects in cancer cells were also observed in multiple
myeloma cell lines resistant to bortezomib, highlighting its potential as a second-line treatment
after relapse [111, 113].
In addition to poly-ubiquitin accumulation, b-AP15 has also been observed to induce oxida-
tive stress and ER stress in cancer cells. This is not uncommon, as other proteasome inhibitors
also induce oxidative stress, however, b-AP15 has also been confirmed as a thioredoxin re-
ductase (TrxR) inhibitor[288, 325], which may cause it to induce higher levels of ROS than
conventional proteasome inhibitors. A significant drawback to the clinical use of b-AP15 is its
limited solubility, nevertheless b-AP15 has been observed to be enriched and retained in cancer
cells [288].
2.11.3 b-AP15 derivatives
Due to the solubility problems of b-AP15, efforts were made to develop similar compounds,
that would display increased solubility and specificity for USP14 [326]. All resulting derivative
retained the α,β-unsaturated ketone motif, which is believed to be responsible for their phar-
macological activity. The optimized lead VLX1570 displayed the lowest IC50 values in HCT116
cells, and was selected for further characterization in Paper I.
VLX1570
The optimized analogue VLX1570 (Figure 2.11), has shown increased solubility in aqueous
solution, as well as high specificity for USP14 and UCHL5, where it acts as a competitive inhibitor
[326]. VLX1570 was subsequently shown to induce apoptosis in multiple myeloma cells in a
manner consistent with the effects of USP14 inhibition, exhibiting poly-ubiquitin accumulation,
oxidative stress and eventual apoptosis (Paper I). The cellular response produced by VLX1570
closely resembles that of b-AP15, and is consistent with proteasome inhibition. Additionally,
VLX1570 has been FDA approved as a treatment for relapsed and refractory multiple myeloma
[327].
Novel enone-containing compounds
Following a similar rationale as the development of the G5/2c inhibitor development [320,
321, 315], Current efforts are going towards identifying other 19S DUB inhibitors from a panel
of compounds that have one or more unsaturated ketones. The prevalence and popularity of
several natural compounds with these α,β-unsaturated ketone motifs, suggests that despite
their proclaimed reactivity, there may be potential clinical applications for them. A screen of
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5000 compounds revealed a range of molecules that display general cytotoxicity, as well as
several potential selective USP14 and UCHL5 inhibitors. Efforts to find additional promising
compounds that target proteasomal deubiquitinases are described in detail in Paper IV.
Chapter 3
Aims of this Thesis
The overall aim of this thesis is to elucidate the mechanism of action of the novel 19S deubiq-
uitinase inhibitor b-AP15 and its derivatives.
While it was repeatedly shown that b-AP15 targets the proteasomal deubiquitinase USP14, the
mechanism by which this induces proteotoxic stress and apoptosis was poorly understood. The
objective of this thesis is to describe the cellular effects of b-AP15 and explain their occurrence.
More specifically, the aims are:
• Describe the effects of b-AP15 and VLX1570 on cancer cells, specifically in multiple
myeloma
• Describe and explain the mechanism of b-AP15-induced mitochondrial damage
• Describe and explain the effects of b-AP15 on aggresome formation and intracellular
transport
• Determine whether related natural compounds, sharing a common unsaturated ketone
chemical motif, will target the proteasome in a similar fashion to b-AP15
• Confirm USP14 as the cellular target of b-AP15 and describe the mechanism of targeting
• Determine the USP14-dependence of b-AP15 induced proteasome inhibition, and the
role of USP14 in proteasomal degradation
Chapter 4
Results
4.1 Paper I: The proteasome deubiquitinase inhibitor VLX1570
shows selectivity for ubiquitin-specific protease-14 and induces
apoptosis in multiple myeloma cells
In this paper we have shown that VLX1570 binds to and inhibits the activity of both USP14 and
UCHL5, but preferentially binds USP14 both in vitro and in multipe myeloma cell lines. Overall
this paper reaffirms the promising anti-proliferative activity of VLX1570/b-AP15 in multiple
myeloma, and suggests that the effects seen are mostly due to inhibition of the proteasomal
DUB USP14.
We have previously shown that VLX1570, the optimized lead based on the b-AP15 com-
pound, is an inhibitor of the proteasomal DUBs USP14 and UCHL5 [288]. At the time, VLX1570
was in clinical trials for relapsed multiple myeloma in the US. We show that multiple myeloma
cell lines treated with VLX1570 show accumulation of poly-ubiquitinated protein substrates
at the proteasome, and eventually undergo apoptosis in a time and dose-dependent manner.
This included multiple myeloma cells that were resistant to the 20S proteasomal inhibitor
bortezomib, and was independent of Bcl-2 status of the cells.
The active site probe Ub-VS showed that USP14 activity was preferentially inhibited by
VLX1570, compared to UCHL5, which was supported by similar results using surface plasmon
resonance (SPR) and thermostabilisation assays (CETSA). We also show that 20S proteolytic
activity is not affected by treatment with VLX1570, nor is poly-ubiquitin association with the
proteasomal ubiquitin receptors.
Incubation of USP14 with Ub-VS reduced binding of VLX1570, suggesting that the com-
pound targets the DUB active site. VLX1570 treament induced higher levels of Hsp70B’, active
caspase 3, Hmox1 and phosphorylated JNK in cells, along with high levels of poly-ubiquitin.
Wash-out experiments additionally indicate that VLX1570 is retained in the cell after uptake,
and can elicit an apoptotic response several hours later. The pro-apoptotic activity of VLX1570
appears to be independent of the anti-apoptotic effects of Bcl2 , as the compound was still
able to induce apoptosis in Bcl2 over-expressing cell lines. It was also unaffected by caspase
inhibitors, suggesting a caspase-independent apoptotic pathway.
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While VLX1570 was able to induce apoptosis in bortezomib-resistant OPM-2 cells (OPM-2
BZR), it displayed a significantly higher IC50 value compared to non-resistant cells (See Figure
4.1), with an increase of about 50%, while IC50 for bortezomib in (OPM-2 BZ
R) was more than
5-fold that of OPM-2. Liquid scintiallation counter experiments using H3-VLX1570 suggested
that the uptake of the drug was reduced in resistant cells, accounting for the increased tolerance.
We also show that OPM-2 BZR cells express high levels of anti-apoptotic proteins such as Bcl2.
Using a lentivirus transfection system, we were able to show that transfection of different
Bcl-2 members could reduce, but not fully eliminated VLX1570-induced apoptosis. Particularly
Bcl2-A1 increased VLX1570 tolerance.
VLX1570 was also tested in two xenograft mouse models of multiple myeloma, where it was
observed to have anti-neoplastic activity. VLX1570 increased survival in an orthotopic multiple
myeloma model using KMS11 cells, while it reduced tumor growth in a subcutaneous model
using RPMI8226 cells. The implanted tumors showed increased poly-ubiquitin levels, higher
levels of Casapase-3 activation and lower levels of phospho-ERK, suggesting reduced activation
of the pro-proliferative Ras/Raf/MEK/ERK pathway [328].
Figure 4.1: IC50 of VLX1570, b-AP15 and bortezomib in multiple myeloma cell lines
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4.2 Paper II: The deubiquitinase inhibitor b-AP15 induces strong
proteotoxic stress and mitochondrial damage
Proteasome inhibition induced by b-AP15 and VLX1570 leads to a build-up of polyubiquitinated
and partially misfolded proteins in the cytosol. These misfolded proteins may interact with
outer mitochondrial membranes, interfering with normal mitochondrial function, and causing
induction of oxidative stress as induced by the mitochondria themselves.
As shown in previous publications, inhibition of the proteasome via blocking of proteaso-
mal DUBs causes cytotoxicity. This cytotoxic effect may be related to oxidative stress, but the
mechanism of apoptosis caused by proteasomal DUB inhibition and accumulation of cytosolic
protein is not known. Paper II shows that pharmacological inhibition of the proteasome induces
proteotoxicity and mitochondrial damage. This effect on mitochondria is associated with the
accumulation of misfolded proteins on the outer mitochondrial membrane.
Using RT-PCR and shotgun proteomics we show that the stress response induced by b-
AP15 closely resembles that of bortezomib. We observe increases in proteins characteristic of
a proteotoxic stress response (Hsp70, JNK, HMOX1 and Hsp40). However, induction of heat
shock proteins was elevated in b-AP15-treated cells compared to those treated with bortezomib.
These findings are consistent with the higher levels of K48-linked poly-ubiquitin found in cells
treated with b-AP15. Isolating poly-ubiquitin chains from treated cells by TUBE assay however,
revealed that the average amount of HSP70B’ associated with poly-ubiquitin chains in b-AP15
treated cells was decreased compared to bortezomib treatment, suggesting the accumulation of
poly-ubiquitinated protein in the cytosol induced by b-AP15 exceeds the cytoprotective capacity
of the heat shock response.
Using immunoelectron microscopy and confocal microscopy, we observed that b-AP15 treat-
ment caused a colocalization of K48-ubiquitin and mitochondria. Western blots of isolated
mitochondria show a dose-dependent increase of poly-ubiquitin in the mitochondrial fraction
of cells treated with b-AP15. Addition of trypsin successfully removed those poly-ubiquitin
chains from the mitochondria, suggesting they are associated with the outer mitochondrial
membrane only. Co-treatment of cells with CpdA - an inhibitor of the Sec61 translocon that
transports unfolded protein into the ER for folding [329] - increased the cytosolic content of
poly-ubiquitinated protein, as well as the amount found on mitochondria. Additionally, expos-
ing mitochondria from untreated cells to the cytosol of b-AP15 treated cells also resulted in
association of poly-ubiquitin with the outer mitochondrial membrane.
Using a Seahorse XF analyzer, we show that the oxygen consumption rate (OCR), a measure
of mitochondrial oxidative phosphorylation, is decreased by exposure to b-AP15. This indicates
mitochondrial damage as a result of b-AP15 treatment. However, we observed no depolarization
of mitochondrial membranes, nor evidence of mitophagy - the autophagic pathway that removes
damaged mitochondria. Autophagic flux in treated cells was not affected by b-AP15 treatment.
Consistent with the absence of mitophagy, we observed no relocalization of the E3 ligase Parkin,
an essential component of mitophagy [330], to the mitochondria. Instead, we observed the
accumulation of the p97/VCP ATPase, a component of the ERAD pathway, possibly in order to
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clear the mitochondrial membrane of damaging unfolded proteins.
These results suggest that mitochondrial damage as a result of proteasome inhibition are
at least partially responsible for the cytotoxic effects of b-AP15.
4.3 Paper III: Proteasome inhibitor b-AP15 induces enhanced
proteotoxicity by inhibiting cytoprotective aggresome formation
In Paper III we show that b-AP15 inhibits ubiquitin dependent aggresome formation in several
cancer cell lines. The lack of aggresome formation may explain the enhanced protetoxicity
observed with b-AP15 treatment, and suggests the potential use of b-AP15 in cancer treatment
as a drug that does not require adjuvant treatment with HDAC inhibitors.
We show here that the proteasomal deubiquitinase inhibitor b-AP15 does not induce cy-
toprotective aggresome formation, despite inhibition of proteasomal degradation. It has been
shown that catalytic inhibition of the proteasome, for example by using bortezomib or MG-132,
leads to the build-up of poly-ubiquitin in the cells. The poly-ubiquitinated proteins cluster in
a single perinuclear inclusion body called aggresomes. Aggresomes are usually found at the
microtubule organizing center (MTOC), and their assembly is mediated by HDAC6, VCP and
p62, and dependent on the cytoskeleton. This however, does not occur in cells treated with the
non-catalytic proteasome inhibitor b-AP15. Instead, confocal imaging shows that poly-ubiquitin
is dispersed in smaller clusters throughout the cytosol. Since aggresome formation is report-
edly cytoprotective, we hypothesized that this lack of aggresome formation is the cause of the
increased proteotoxicity observed with our line of proteasome deubiquitinase inhibitors, and
may explain the mitochondrial toxicity observed in Paper II.
Using the HDAC inhibitor SAHA, we show that inhibition of HDAC6 had no additive effects
with b-AP15, while showing strong synergy with bortezomib. Confocal imaging shows that
b-AP15 does not cause dissociation of the microtubule network. TUBE assays of isolated poly-
ubiquitin show that b-AP15 does not prevent the association of HDAC6, VCP or p62 with
poly-ubiquitin. However, treatment with b-AP15 caused a slight increase ubiquitination of
HDAC6 itself. Interestingly, our confocal data shows that co-treatment of HeLa cells with b-AP15
and bortezomib also does not result in aggresome formation. The interference of b-AP15 with
aggresome formation therefore displays a dominant negative effect over bortezomib, indicating
that it acts upstream of substrate trafficking to the aggresome. Consistent with these results
our confocal microscopy data shows a rearrangement of clathrin-coated vesicles as well as
mitochondria, both of which depend on motor-protein mediated transport for trafficking. Using
protetomics data derived from isolated mitochondria, we show that while the mitochondrial
transport machinery remains intact, non-mitochondrial proteins are now found associated with
mitochondria. This suggests a general transport defect, resulting in a "traffic jam" scenario.
We conclude that b-AP15 has an inhibitory effect on motor-protein dependent transport,
which results in cytotoxic protein aggregates remaining in the cytosol, rather than being traf-
ficked and sequestered into the aggresome for autophagic clearance. This explains the enhanced
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protetoxic response elicited by b-AP15 treatment, as well as the mitochondrial effects described
in Paper II.
4.4 Paper IV: Cytotoxic unsaturated electrophilic compounds
commonly target the ubiquitin proteasome system
In this paper, we conducted a drug screen of compounds selected for unsaturated ketone
(enone) motifs, such as the α,β- unsaturated ketones found in b-AP15, VLX1570 and G5/2c
as well as the natural products curcumin, piperlongumine and gambogic acid [331, 332, 333].
The objective was to determine whether these compounds have a discernible mode of action,
despite their proclaimed promiscuity.
Using a panel of 5000 compounds, we performed a drug screen of molecules carrying single
or double unsaturated ketone motifs, with the goal of finding and developing other inhibitors
of the UPS, primarily of the 19S associated deubiquitinases USP14 and UCHL5. This approach
is based on the observed structural elements shared between known 19S DUB inhibitors, such
as curcumin, piperlongumine, AC17, b-AP15 and VLX1570, all of which carry one or more
Michael acceptors. The screen, using a ubiquitin-YFP (UbG76V -YFP) expressing reporter cell
line, yielded 59 compounds that showed ubiquitin-YFP accumulation, indicating proteasome
inhibition. Out of those compounds, 10 induced Ub-YFP in over 50 percent of cells. These 10
compounds were then investigated for their ability to induce K48-Ub accumulation, inhibition
of proteolytic activity of the proteasome, and mechanism of induction of apoptosis. A summary
of their properties is shown in Table 4.1.
Consistent with proteasome inhibition, the hit compounds induced increased levels of
Hsp70B’, as well as HMOX1, indicating both proteotoxic and oxidative stress. ER stress marker
elF2α and spliced XBP1 were also induced, anlong with apoptotic marker Caspase 3. As with
b-AP15, the poly-ubiquitin accumulating in treated cells was shown to cosediment with pro-
teasomes in glycerol gradient fractionation, ruling out inhibition of the Rpn13 proteasomal
ubiquitin receptor.
Hit ID Ub-YFP USP14 binding Antineoplastic effects Developmental toxicity
CB360 ++ - ++ -
CB997 ++ + + +
CB686 ++ + +
CB688 + + -
CB113 ++ + ++ -
CB729 ++ + + +
CB742 + + +
CB916 ++ + ++ -
CB826 ++ + ++ +
CB383 ++ + -
Table 4.1: Properties of hit compounds containing α,β-unsaturated ketone motifs
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The DUB active site probe Ub-VS was used to test the inhibition of deubiquitinases, re-
vealing inhibition of both 19S DUBs, without effects on other DUBs tested. Association of the
several of the compounds with USP14 and UCHL5 was additionally confirmed using Isothermal
Calorimetry (ITC), as well as Cellular Extract Thermostabilisation Assay (CETSA). MALDI-TOF
mass spectrometry was used to assay molecular mass shifts of USP14 after incubation with hit
compounds, and revealed binding for all hits, except CB360. Tryptophan fluorescence showed
binding of CB729 and CB916 to the USP14 catalytic domain. Inhibition of cancer cell growth
was also confirmed in zebrafish embryos.
Since b-AP15 and VLX1570 are known TrxR inhibitors, all compounds that showed cytotoxic
effects were also tested for TrxR inhibition. Some compounds inhibited the proteasome without
TrxR inhibition, some inhibited only TrxR and some inhibited only the proteasome. None of
the 10 UPS inhibiting hits inhibited TrxR. This confirms that the cytotoxic effects observed
with 19S DUB inhibitors are not only due to off-target effects on TrxR and inhibited oxidative
stress response, and that inhibition of USP14 and UCHL5 alone is effective in inhibiting cancer
growth.
We demonstrate that a substantial fraction ( 20%) of cytotoxic synthetic compounds con-
taining Michael acceptor groups inhibit proteasome substrate processing and induce a cellular
response characteristic of proteasome inhibition. Additionally, biochemical and structural anal-
ysis shows inhibition of proteasome-associated cysteine deubiquitinases. We identified a subset
of cytotoxic compounds where cell death induction was closely associated with proteasome
inhibition. These compounds also showed antineoplastic activity in a zebrafish embryo model,
with variable developmental toxicity.
Our findings suggest that proteasome inhibition is a relatively common mode of action by
compounds containing Michael acceptor groups. These results explain previous reports on the
anti-cancer activity of natural products containing such functional groups, and suggests their
use in pharmacological application.
4.5 Paper V: Studies on the specificity of the deubiquitinase
inhibitor b-AP15
In this paper we generated a targeted knock-out cell line that is USP14 negative using CrispR/Cas9
generated HCT116 colon carcinoma cells. We used this cell line to determine the dependency
of b-AP15 effects on the proteasomal deubiquitinase USP14.
Using the USP14 negative cell line we were able to show that the inhibitory effects of
b-AP15 are partially dependent on USP14, further supporting the suggested partial selectivity
of compounds containing reactive motifs, such as b-AP15 and the hit compounds described
in Paper IV. We do however show that other factors contribute to the proteasome inhibition
observed with b-AP15. Our siRNA knockdown of USP14 and UCHL5 show that while removal
of a single 19S DUB triggers increases in poly-ubiquitin levels, removal of USP14 alone does
not produce as severe an increase as b-AP15 treatment. Dual knockdown of both USP14 and
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UCHL5 produced poly-ubiquitin levels more closely resembling those of b-AP15 treatment. This
suggests that USP14 inhibition alone cannot account for the effect observed with b-AP15.
USP14−/− cells initially showed a decrease in doubling times, and displayed various mor-
phological changes. Ub-VS labeling of DUBs showed no compensatory increase in other deu-
biquitinases in USP14−/− cells. Treatment of USP14−/− cells with b-AP15 resulted in a slight
increase in K48 poly-ubiquitin levels, while MTT survival assays showed that the USP14−/−
cells had a ∼2-fold increase in IC50. USP14 is therefore required to produce the full cellular
response to b-AP15.
We designed myc-tagged constructs of USP14 with various mutations of the catalytic
triad (C114, H435 and D451), and transiently transfected them into USP14−/− cells. The
constructs were well expressed, and the catalytic mutants produced a pronounced increase
in poly-ubiquitin levels compared to the knock-out cells. Mutations of the catalytic cysteine
(C114A, C114S) resulted in the strongest increase in poly-ubiquitin. Colony formation assays
showed that the mutations reduced clonogenic potential, particularly the C114A and C114S
mutants. A proposed model explaining the remaining sensitivity of USP14−/− cells to b-AP15
is shown in Figure 4.2.
Without access to a UCHL5−/− cell line, we used a yeast model expressing homologues of
the human 19s DUBs. The USP14 homologue ubp6 and the UCHL5 homologue uch2 are both
expressed in S. pombe. We used strains defective in one of the deubiquitnases to test for b-AP15
sensitivity. While Ubp6+/Uch2− cells showed increased sensitivity to b-AP15, Ubp6−/Uch2+
were less sensitive, consistent with the data from the USP14−/− cell line.
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Figure 4.2: Model explaining the remaining partial sensitivity of USP14−/− cells to b-AP15. A likely
explanation is that UCHL5 takes over ubiquitin processing following USP14 deletion, and that the
remaining sensitivity to b-AP15 can be explained by the previously documented targeting of UCHL5
by b-AP15. Alternatively, a different DUB (DUB X) takes over for USP14, and is likewise affected by
b-AP15.
Chapter 5
Discussion
5.1 Cellular effects of b-AP15 and VLX1570
In Paper I we set out to test the binding capabilities and cytotoxic effects of VLX1570, an
optimized lead of the proteasomal DUB inhibitor b-AP15. A continuing problem with the b-
AP15 compound is its limited solubility, preventing useful clinical application. Derivatives with
increased solubility were therefore synthesized and characterized [326]. VLX1570 retains the
α-,β-unsaturated ketone structure characteristic of b-AP15, and was therefore expected to
similarly target the DUB catalytic cysteines.
Using Ub-VS and SPR binding assays, we show here that VLX1570 displays binding capabil-
ities very similar to those of b-AP15. Like b-AP15 it also appears to be a reversible inhibitor of
both USP14 and UCHL5, where it is thought to bind the active site. We consistently show pref-
erential targeting of USP14 over UCHL5. Interestingly, despite SPR data suggesting reversible
binding, a washout experiment with VLX1570 indicates that despite removal of the drug from
the extracellular medium after only 1h of exposure, the proteasomal DUBs remain inhibited
and bound to VLX1570. We observed no recovered DUB activity after 17h of washout. However,
we were able to reconcile these results by determining that, like b-AP15 [288], VLX1570 is
rapidly taken up into the cells, where it is retained, even upon washout.
Paper I also characterizes the cytotoxic effects displayed by VLX1570, which include in-
duction of Hsp70B’ (HSP6A), HMOX1 and JNK, as well as accumulation of K48-linked poly-
ubiquitin. Hsp70B’ is a stress-induced chaperone, that is commonly activated by proteasome
inhibition [334], HMOX-1 is induced in response to oxidative stress and cellular heat shock con-
ditions [335, 336], and JNK is a component of both intrinsic and extrinsic apoptotic pathways,
and is commonly induced by ER stress [210, 337]. Together, this profile of stress activated
proteins supports the inhibition of proteasomal degradation by VLX1570, and are consistent
with a cellular proteotoxic stress response.
Paper I and several previous publications [322, 323, 324, 325, 338] show that inhibition of
the proteasome via blocking of its deubiquitinating activity leads to cellular proteotoxicity. The
cytotoxicity of this effect may be related to oxidative stress caused by proteasome inhibition.
However, the exact mechanism of the apoptotic effects caused by b-AP15 and its derivative
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VLX1570 is not fully understood. Paper II further investigates the mechanism by which b-AP15
triggers apoptosis, and shows that UPS inhibition manifests as proteotoxicity and impaired
mitochondrial function.
While we see a reduction in OCR as a result of b-AP15 exposure, as well as severe structural
deformation of mitochondria, there is no evidence of mitophagy. Under normal conditions,
mitochondrial damage is indicated by a reduction in mitochondrial membrane potential. This
depolarization causes the accumulation of the kinase PINK1 on the outer mitochondrial mem-
brane. PINK1 recruits the E3 ligase Parkin to mitochondria. Parkin then marks the mitochondria
for autophagic clearance by tagging them with K63-linked ubiquitin chains [330, 339]. This
PINK1-Parkin-mitophagy pathway is not activated by b-AP15, despite evidence of mitochon-
drial damage. Instead we have observed p97/VCP ATPase accumulation on mitochondria. It
is possible that p97/VCP is recruited to the mitochondria, in response to b-AP15 treatment, in
order to facilitate removal of unfolded and damaging protein, and to restore mitochondrial
function.This is supported by our results showing that inhibition of p97/VCP caused higher
levels of misfolded proteins to accumulate on mitochondrial membranes, as well as more severe
OCR reduction. We have developed a model mechanism to explain this phenomenon (Figure
5.1).
While the details of how b-AP15 causes mitochondrial damage, and the absence of mi-
tophagy despite mitochondrial damage, still remains to be determined, these results suggest
that proteasomal inhibition by b-AP15 causes an overload of the heat shock system. This leads
to accumulation of partially unfolded proteins in the cytosol. Exposed hydrophobic patches on
these proteins may interfere with organelle membranes, including mitochondria.
Cytosolic unfolded and/or poly-ubiquitinated proteins have been shown to sequester into
the single large perinuclear inclusion body called the aggresome. Aggresomes are usually found
at the MTOC. As a continuation of the work in Paper II, we show in Paper III that no aggresomes
form in cells treated with b-AP15. Instead poly-ubiquitin can be seen spread in smaller clusters
throughout the cytosol. We hypothesized that since aggresome formation is cytoprotective,
the lack of aggresome formation is the cause of the increased proteotoxicity observed with
our line of proteasome deubiquitinase inhibitors. Our results have shown that b-AP15 inhibits
aggresome formation in a ubiquitin-dependent manner, but that it does not interfere with the
recruitment of the aggresome machinery to the poly-ubiquitinated protein. We considered
the possibility that the lack of transport of these poly-ubiquitinated proteins was somehow
dependent on the chain length of the ubiquitin itself. However, with no way to isolate and
examine the contents of b-AP15-induced aggregates, we were unable to pursue this thought
further. We show that b-AP15 does not inhibit HDAC6 deacetylation activity, nor does it lead to
microtubule hyperacetylation or dissociation. However, treatment with b-AP15 caused a slight
increase in poly-ubiquitinated HDAC6 itself. It is possible that poly-ubiquitination of HDAC6
renders the enzyme non-functional in aggresome formation, for example by interfering with
the turnover between VCP and HDAC6.
We have also shown that while there are increased levels of poly-ubiquitin chains visible
in the cytoplasm following b-AP15 treatment, some of these chains co-precipitate with the
5. Discussion 43
USP14
UCHL5
b-AP15
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Ub
Poly-ubiquitinated protein
Mitochondria
p97/VCP
p97/VCP
p97/VCP
p97/VCP
ROS
Clearance & Survival
Apoptosis
Figure 5.1: Mitochondria-mediated apoptosis in response to b-AP15 treatment. Proteasome inhibition
by b-AP15 causes cytosolic accumulation of partially unfolded proteins that interfere with the outer
mitochondrial membrane. The ATPase p97/VCP is recruited to clear and restore mitochondria.
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proteasome in glycerol gradients, suggesting they are at least transiently associated with the
proteasome.
Since we found no obvious defect with components of the aggresome machinery, we inves-
tigated whether the trafficking of other substrates of microtubule transport was also affected
by b-AP15. We show that already at early timepoints the distribution of clathrin-coated vesicles
as well as mitochondria, was affected by b-AP15, indicating a more general defect in trafficking
along microtubules.
We suggest that the aggresome defect in b-AP15 treated cells is due to either direct on
indirect interference of b-AP15 with motor-protein dependent transport along microtubules.
This could either be due to direct action of b-AP15 on a component of transport machinery, or
b-AP15 dependent inhibition of a deubiquitinase that is required for trafficking. It appears that
both, anterograde and retrograde transport are affected, since protein aggregates are not being
transported towards the nucleus, while vesicles and mitochondria appear to cluster in proximity
to the nucleus without being moved towards the periphery of the cell. Our tentative model of
the effect (shown as Figure 7 in Paper III) proposes a scenario akin to a traffic jam. Without
functional transport, trafficking substrates pile up in close proximity of one another, allowing
for the damaging interactions of partially unfolded protein with mitochondrial membranes
(Paper II), as well as the association of various centrosomal proteins with isolated mitochondria
seen in Paper III.
5.2 Biochemical basis of b-AP14 effects and role of USP14
5.2.0 α-,β- unsaturated ketones as DUB inhibitors
A large number of natural compounds have recently been suggested as potential anticancer
agents, frequently with unclear or unknown mechanisms of action. Many of these compounds
contain functional groups characterized by high chemical reactivity. Researchers and reviewers
are often wary of such chemicals, considering them to be too promiscuous to be pharmaco-
logically useful. In fact, identifying which compounds contain so called pan assay interference
compounds (PAINS) motifs (i.e. highly reactive functional groups such as unsaturated carbon
moieties) is often used to disqualify molecules from drugscreens [340, 341]. Yet, several nat-
ural compounds, that have been generating a lot of interest in the phamacological research
community, contain PAINS. Examples include piperlongumine [332], gambogic acid [333] and
curcumin [331], all of which contain reactive α,β - unsaturated ketones. The α,β -unsaturated
ketone motif has repeatedly been reported to be responsible for the phamacological activity of
these compounds. This is supported by our findings in Paper I showing that another b-AP15
derivative, VLX1680, with only a single unsaturated carbonyl, displayed lower anti-neoplastic
activity than VLX1570 or b-AP15. The α,β -unsaturated ketone motif has even been suggested
as a phamacophore model for the development of additional DUB inhibitors [296].This indi-
cates that PAINS do not universally display general cytotoxicity, and can in fact have a certain
degree of selectivity, making them pharmacologically useful.
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Our DUB inhibitor b-AP15 also contains an α,β-unsaturated ketone motif, and has con-
sistently been shown to selectively target USP14. The presence of the same functional group
in a broad spectrum of DUB inhibitors indicates that targeting of DUBs may be a common
mechanism for these types of reactive, unsaturated molecules, and motivated the drug screen
we performed for Paper IV.
The hits resulting from the screen all contain one or two unsaturated ketones, and display at
least partial selectivity for 19S DUBs. Additionally, in docking experiments, the hits consistently
mapped into the USP14 active site, and did not visibly inhibit other deubiquitinases. Additionally,
of the four hits that did not display developmental toxicity at any dose, three were classified
as PAINS, adding another indication that PAINS are not destined to be generally cytotoxic.
Several α-,β -unsaturated ketones, including b-AP15 are known to inhibit thioredoxin reduc-
tase 1 (TrxR1), which has an exceptionally reactive catalytic selenocysteine residue, a preferred
target of electrophilic compounds. While several of the compounds determined to be UPS in-
hibitors in Paper IV, also inhibited TrxR, none of the 10 hit compounds did. TrxR inhibition
therefore cannot be the main effector of the oxidative and proteotoxic stress observed with
these compounds.
Another potential target of these reactive compounds that could result in similar proteotoxic
effects is the proteasomal ubiquitin receptor Rpn13. The small molecule inhibitor RA-190,
which selectively targets Rpn13 to inhibit proteasomal degradation closely resembles b-AP15
and VLX1570 [342]. This raises the possibility that the observed proteotoxic effects in Paper IV
are due to inhibition of ubiquitin binding to the proteasome. We have however repeatedly
shown that b-AP15, VLX1570 and all of the 10 hits in Paper IV have no effect on poly-ubiquitin
association with the proteasome, ruling out effects on Rpn13.
In addition to the selectivity displayed by b-AP15 [323], VLX1570 [Paper I], and the hit
compounds [Paper IV], we show in Paper V that the effects on b-AP15 are primarily dependent
on USP14. While there must be some off-target activity to account for the remaining sensitivity
to b-AP15 in USP14−/− cells, the primary target through which b-AP15 manifests its proteotoxic
effects is USP14.
The unifying conclusion of Paper IPaper IV and Paper V reinforces the potential of b-AP15
and other molecules like it in pharmacological application, particularly in cancer therapy.
5.2.0 USP14 in proteasomal degradation
19S deubiquitinases are confirmed viable targets in cancer therapy. Effects of inhibition consis-
tently show decreased protein degradation, poly-ubiquitin accumulation, proteotoxicity and
eventually apoptosis. Their non-genotoxic nature makes small molecule inhibitors of the UCHL5
and USP14 DUBs, such as b-AP15, AC17 and VLX1570, promising candidates for development
into cancer treatment.
Targeting USP14 in cancer treatment takes advantage of it pro-proteolytic activity in pro-
teasomal degradation. However, it has been suggested that USP14 actually has the opposite
function and actually prevents protein degradation by deubiquitinating substrates and rescu-
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ing them from proteolysis. Inhibition of USP14 would then accelerate proteasomal hydrolysis
[343]. Several papers have been published supporting either of the two seemingly opposing
functions of USP14.
Recent research has suggested that inhibition of USP14 with IU1 increases tau degradation
[344], and that upregulation of proteasomal degradation via USP14 inhibition by IU1 impairs
autophagic flux [345], suggesting USP14 also works as a regulatory switch between proteolysis
and autophagy.
IU1 is the inhibitor most commonly used in the studies investigating enhancing proteolysis
via USP14 inhibition [114, 346]. It was recently reported to have been co-crystallized with
USP14, where it binds to a unique pocket in proximity to the catalytic triad. Its mechanism of
inhibition is therefore steric interference, by preventing access of the ubiquitin C-terminal to the
catalytic site of USP14 [347]. This distinguishes it from the α-,β -unsaturated ketone-containing
inhibitors, which are thought to interact with the catalytic cysteine, as well as blocking access
to the catalytic site (See Figure 5.2B).
Our research offers several counter-indications to the idea that USP14 plays a role in prevent-
ing proteasomal degradation. Knockdown of USP14 using siRNA in Paper V showed reduced
cellular viablity and increased levels of poly-ubiquitin. Likewise, the USP14−/− cell line dis-
played slower proliferation, and transient transfection of wt USP14 did not lead to an increase
in poly-ubiquitin levels, indicating USP14 does not act to slow down proteasomal degradation.
Interestingly, in Paper I we find no evidence of thermostabilization in CETSA assays of USP14
by IU1. This may however be due to dissociation of USP14 from the proteasome at high temper-
ature (discussed in Paper IV). In Paper V we show that treatment with IU1 does in fact lead to
an increase in cellular poly-ubiquitin levels, suggesting no enhancement of proteasome activity
via the reported inhibition of USP14. We have thus been unable to confirm IU1-dependent en-
hancement of proteolytic activity, as have other research groups [348]. However, a significant
body of evidence indicates that IU1 does in fact specifically target USP14, but does not have
cytotoxic effects. This is an indication that b-AP15 must have alternative cellular targets to
produce its full effect.
A recent publication took up an intermediate position [349], suggesting that it is the USP14
Ubl domain that promotes proteasomal degradation by binding to the proteasome, indepen-
dently of USP14 catalytic activity. As part of out USP14 mutant studies in Paper V, we transiently
transfected a myc-tagged construct of the USP14-Ubl domain into the HCT116 USP14−/− cell
line, but were unable to confirm an increase in proteolytic activity, as poly-ubiquitin levels did
not decrease (unpublished data). It is possible that the construct was improperly folded or
expressed, and its functionality would need to be confirmed e.g. by native gel electrophoresis
before fully trusting these results.
Overall, the data presented in the constituent papers of this thesis supports the role of
USP14 as complementary to POH1 activity and an integral component of protein degradation
by the proteasome. [111, 113, 350, 351]. The mechanism of ubiquitin-trimming by USP14 at
the proteasome, the effects of b-AP15 or IU1, as well as USP14 catalytic mutation or knockout
are summarized in Figure 6.2.
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Figure 5.2: USP14 activity and role in proteasomal degradation A) Under normal conditions USP14
trims K48-linked poly-ubiquitin chains from the distal end in preparation for substrate degradation by
the 26S proteasome
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B) Inhibition of USP14 by b-AP15 blocks access of the ubiquitin C-terminal to the catalytic site, while
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D) USP14 knockout conditions. Proteasomal deubiquitinating activity is taken over by another DUB
(possibly UCHL5), which resolves proteotoxic stress and promotes cell survival
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5.3 Ethical Considerations and Limitations
The majority of this project does not involve any patient materials. All work is performed in
established cells lines for the cancer types of interest. One concern might be the ethical initial
sourcing of those cell lines. In the past there have been conflicts, especially concerning the
HeLa cervical cancer cell line. HeLa cells are widely used without credit being given to the
original donor Henrietta Lacks, or her family. We have also been using HeLa cells for a selection
of experiments, and are aware of these problems. Patient samples - whether it be primary cells
or established cell line obtained from patient derived cells - should always be obtained with
informed consent, and only under the appropriate ethical permits.
The animal experiments in Paper I were performed by Nerviano Medical Science under the
appropriate EU ethical guidelines.
Work carried out exclusively in cell lines has obvious limitations in terms of applicability in
humans. It is a very artificial system that in no way resembles the conditions in the human body.
Recently attention has also been brought to the issue of reproducibility in medical research,
some of which may be due to contamination or mutation of cell lines used in the laboratory.
Regularly sequencing cell lines to ensure that they are the correct cells is recommended. Ad-
ditionally, differences between cell lines also presents issues. Results obtained in one type of
cell may not apply in another, making it challenging to determine promising drug candidates
to test further.
Chapter 6
Conclusions
The results presented in this thesis contribute to the body of scientific evidence regarding the
use of proteasome inhibitors in cancer therapy. Particularly we focus on the applications of
inhibitors of the 19S proteasomal ubiquitinases as an alternative to conventional UPS inhibitors
such as bortezomib, that have a high incidence of resistance. This body of work adds to our
understanding of the cellular effects induced by inhibition of the 19S DUB USP14, as well as
the function and interplay of the proteasomal deubiquitinases.
Additionally, we have investigated the potential applications of reactive enone compounds
in a phamacological setting. By demonstrating their selectivity, despite being highly reactive,
we hope to make a case for continued research into the uses of these types of compounds.
In summary, we conclude the following:
• The small molecule inhibitor b-AP15 targets the 19S deubiquitinase USP14 [Paper I].
• Mitochondrial damage is a direct result of b-AP15 induced protein accumulation in the
cytosol [Paper II].
• Proteasome inhibition by b-AP15 does not trigger aggresome formation, leading to en-
hanced proteotoxicity and mitochodrial damage [Paper III].
• Compounds containing reactive α,β- unsaturated ketones can exhibit partial selectivity
for 19S deubiquitinases and have potential pharmacological application [Paper IV].
• USP14 is the primary target of b-AP15, and an effector of b-AP15-induced proteotoxicity
[Paper V].
Chapter 7
Future Perspectives
Based on the conclusions presented in this thesis, potential future research directions include:
• Generation and characterization of a UCHL5−/− cell line to confirm results presented
in Paper V. Judging by the sensitivity of S.pombe to b-AP15, it can be expected that
UCHL5−/− cells will be less sensitive to b-AP15, as they are dependent on USP14 alone.
• Conditional knock-out studies of USP14 in mice. USP14−/− mice have previously been
reported to suffer from ataxia [352], but our preliminary results suggest that total ho-
mozygous USP14 knockout is lethal in utero. We are therefore aiming for a tissue specific
knockout of USP14.
• Further investigation of the mechanism by which 19S DUB inhibition induces cell death
and interferes with trafficking, particularly the involvement of the motor proteins dynein
and kinesin.
• Proteome Mass Spectrometry of the USP14−/− and UCHL5−/− cell lines to determine
alterations in ubiquitination patterns, to further elucidate the role of the two DUBs in
proteasomal degradation, as well as microarrays to determine altered gene expression.
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